

INVENTOR SEARCH

=> fil capl; d que nos 125

FILE 'CAPLUS' ENTERED AT 13:06:28 ON 12 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Sep 2007 VOL 147 ISS 12

FILE LAST UPDATED: 11 Sep 2007 (20070911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos 148

```

L4          STR
L8          7166 SEA FILE=REGISTRY SSS FUL L4
L19         979 SEA FILE=CAPLUS ABB=ON  BALZARINI J?/AU
L20         481 SEA FILE=CAPLUS ABB=ON  PREOBRAZHENS KAYA M?/AU
L21         2099 SEA FILE=CAPLUS ABB=ON  DECLERCQ E?/AU OR DE CLERCQ E?/AU
L32         STR
L33         STR
L34         STR
L39         3 SEA FILE=REGISTRY SUB=L8 SSS FUL (L32 OR L33 OR L34)
L47         4 SEA FILE=CAPLUS ABB=ON  L39
L48         4 SEA FILE=CAPLUS ABB=ON  (L19 OR L20 OR L21) AND L47

```

=> d ibib abs hitstr 148 1-4

L48 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:876847 CAPLUS

DOCUMENT NUMBER: 145:465216

TITLE: Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics

AUTHOR(S): Balzarini, Jan; Keyaerts, Els; Vijgen, Leen; Egberink, Herman; De Clercq, Erik; Van Ranst, Marc; Printsevskaya, Svetlana S.; Olsufyeva, Eugenia N.; Solovieva, Svetlana E.; Preobrazhenskaya, Maria N.

CORPORATE SOURCE: Rega Institute for Medical Research, K.U. Leuven, Louvain, B-3000, Belg.

SOURCE: Antiviral Research (2006), 72(1), 20-33

CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Various semisynthetic derivs. of glycopeptide antibiotics including vancomycin, eremomycin, teicoplanin, ristocetin A and DA-40926 have been evaluated for their inhibitory activity against feline infectious peritonitis virus (FIPV) and human (SARS-CoV, Frankfurt-1 strain) coronavirus in cell culture in comparison with their activity against human immunodeficiency virus (HIV). Several glycopeptide derivs. modified with hydrophobic substituents showed selective antiviral activity. For the most active compds., the 50% effective concns. (EC50) were in the lower micromolar range. In general, removal of the carbohydrate parts of the mols. did not affect the antiviral activity of the compds. Some compds. showed inhibitory activity against both, whereas other compds. proved inhibitory to either, FIPV or SARS-CoV. There was no close correlation between the EC50 values of the glycopeptide derivs. for FIPV or SARS-CoV.

IT 562105-30-0 562105-47-9 855674-07-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(inhibition of FIPV and human SARS coronavirus by semisynthetic derivs. of glycopeptide antibiotics)

RN 562105-30-0 CAPLUS


CN Ristomycin A aglycone, 38-[[[(6-aminohexyl)amino]carbonyl]-22,31-dichloro-41-[[[3-(decyldimethylammonio)propyl]amino]methyl]-38-de(methoxycarbonyl)-7-demethyl-19-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 562105-47-9 CAPLUS


CN Glycine, (2R)-2-[3-[4-[(2R)-2-carboxy-2-[(phenylmethoxy)carbonyl]amino]ethyl]-2-chlorophenoxy]-4,5-dihydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl-(.beta.R)-3-chloro-.beta.-hydroxy-L-tyrosyl-, 4-methyl ester, cyclic (15.fwdarw.34)-ether, cyclic 22,42-[4,6,6'-trihydroxy-5-[(tricyclo[3.3.1.1^{3,7}]dec-2-ylamino)methyl][1,1'-biphenyl]-3',2-diyl] deriv., [2(2R),4(2S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 855674-07-6 CAPLUS


CN Vancomycin, 44-O-de[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-.alpha.-L-lyxohexopyranosyl)-.beta.-D-glucopyranosyl]-26-decarboxy-26-[[tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:383224 CAPLUS

DOCUMENT NUMBER: 143:70993

TITLE: Structure-Activity Relationship Studies of a Series of Antiviral and Antibacterial Aglycon Derivatives of the Glycopeptide Antibiotics Vancomycin, Eremomycin, and Dechloroeremomycin

AUTHOR(S): Printsevskaya, Svetlana S.; Solovieva, Svetlana E.; Olsufyeva, Eugenia N.; Mirchink, Elena P.; Isakova, Elena B.; De Clercq, Erik; Balzarini, Jan; Preobrazhenskaya, Maria N.

CORPORATE SOURCE: Gause Institute of New Antibiotic, Russian Academy of Medical Sciences, Moscow, 119021, Russia

SOURCE: Journal of Medicinal Chemistry (2005), 48(11), 3885-3890

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:70993

AB N-(Adamantyl-1)methyl, N-(adamantyl-2), and N-(.omega.-aminodecyl) amides of vancomycin, eremomycin, and dechloroeremomycin aglycons and their des-(N-Me-D-Leu) derivs. were synthesized and their antibacterial and anti-HIV activities were investigated. Carboxamides with an intact peptide core demonstrated activity against glycopeptide-susceptible and -resistant bacteria (1-32 .mu.M). N-(Adamantyl-1)methylcarboxamide of

eremomycin aglycons had good antiretroviral activity (1.6 μM against HIV-1). Compds. with destroyed peptide core [des-(N-Me-D-Leu)-aglycon amides] were inactive against both glycopeptide-sensitive and -resistant bacteria. (Adamantyl-1)methylamide of des-(N-Me-D-Leu)-eremomycin aglycon had good antiretroviral activity (EC_{50} of 5.5 μM for HIV-1 and 3.5 μM for HIV-2). (Adamantyl-1)methylamides of eremomycin aglycon and its des-(N-Me-D-Leu)-deriv. are the most promising and selective antiretroviral agents. Their ability to induce bacterial resistance to glycopeptide antibiotics during prolonged administration may be expected to be very low or absent. This might make the use of these derivs. feasible in the prolonged therapy or prophylaxis of HIV infections.

IT 855674-07-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(structure-activity relationship of antiviral and antibacterial aglycon derivs. of glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin)

RN 855674-07-6 CAPLUS


CN Vancomycin, 44-O-de[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-.alpha.-L-lyxohexopyranosyl)-.beta.-D-glucopyranosyl]-26-decarboxy-26-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:203690 CAPLUS

DOCUMENT NUMBER: 140:247018
 TITLE: Glycopeptide antibiotic derivatives, their preparation and their use as antiviral agents
 INVENTOR(S): Balzarini, Jan; Preobrazhenskaya, Maria; De Clercq, Erik
 PATENT ASSIGNEE(S): K.U. Leuven Research and Development, Belg.
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019970	A2	20040311	WO 2003-BE144	20030901
WO 2004019970	A3	20040722		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497159	A1	20040311	CA 2003-2497159	20030901
AU 2003260198	A1	20040319	AU 2003-260198	20030901
EP 1534316	A2	20050601	EP 2003-790574	20030901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503015	T	20060126	JP 2004-531311	20030901
CN 1741810	A	20060301	CN 2003-824842	20030901
US 2005250677	A1	20051110	US 2005-525784	20050228
IN 2005KN00528	A	20060224	IN 2005-KN528	20050330
IN 2007KN01836	A	20070810	IN 2007-KN1836	20070523
PRIORITY APPLN. INFO.:				
			GB 2002-20235	A 20020830
			GB 2002-20233	A 20020831
			GB 2003-10890	A 20030425
			GB 2003-9521	A 20030425
			WO 2003-BE144	W 20030901
			IN 2005-KN528	A3 20050330

OTHER SOURCE(S): MARPAT 140:247018

AB Glycopeptide antibiotic derivs., processes for their prepn., their use as a medicine, their use to treat or prevent viral infections and their use to manuf. a medicine to treat or prevent viral infections are provided. The invention discloses the use of glycopeptide antibiotics and their semisynthetic derivs. to treat or prevent viral infections and their use to manuf. a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses belonging to Retroviridae, Herpesviridae, Flaviviridae and the Coronaviridae, like HIV (human immunodeficiency virus), HCV (hepatitis C virus), BVDV (bovine viral diarrhea virus), SARS (severe acute respiratory syndrome)-causing virus, FCV (feline coronavirus), HSV (herpes simplex virus), VZV (varicella zoster virus) and CMV (cytomegalovirus).

IT 562105-30-0P 562105-47-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(glycopeptide antibiotic derivs., prepn. and use as antiviral agents)

RN 562105-30-0 CAPLUS


CN Ristomycin A aglycone, 38-[[[(6-aminohexyl)amino]carbonyl]-22,31-dichloro-41-[[[3-(decyldimethylammonio)propyl]amino]methyl]-38-de(methoxycarbonyl)-7-demethyl-19-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 562105-47-9 CAPLUS


CN Glycine, (2R)-2-[3-[4-[(2R)-2-carboxy-2-[[[(phenylmethoxy)carbonyl]amino]ethyl]-2-chlorophenoxy]-4,5-dihydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl-(.beta.R)-3-chloro-.beta.-hydroxy-L-tyrosyl-, 4-methyl ester, cyclic (15.fwdarw.34)-ether, cyclic 22,42-[4,6,6'-trihydroxy-5-[(tricyclo[3.3.1.1.3,7]dec-2-ylamino)methyl][1,1'-biphenyl]-3',2-diyl] deriv., [2(2R),4(2S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L48 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:397187 CAPLUS

DOCUMENT NUMBER: 139:111130

TITLE: Antiretroviral Activity of Semisynthetic Derivatives of Glycopeptide Antibiotics

AUTHOR(S): Balzarini, Jan; Pannecouque, Christophe; De Clercq, Erik; Pavlov, Andrey Y.; Printsevskaya, Svetlana S.; Miroshnikova, Olga V.; Reznikova, Marina I.; Preobrazhenskaya, Maria N.

CORPORATE SOURCE: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.

SOURCE: Journal of Medicinal Chemistry (2003), 46(13), 2755-2764

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

AB A variety of semisynthetic derivs. of natural antibacterial glycopeptide antibiotics such as vancomycin, eremomycin, ristocetin A, teicoplanin A2-2, DA-40926, their aglycons, and also the products of their partial degrdn. with a destroyed or modified peptide core show marked anti-retroviral activity in cell culture. In particular, aglycon antibiotic derivs. contg. various substituents of a preferably hydrophobic nature displayed activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and Moloney murine sarcoma virus at a 50% inhibitory concn. in the lower micromolar (1-5 .mu.M) concn. range while not being cytostatic against human lymphocytic cells at 250 .mu.M or higher. The mode of anti-HIV action of the antibiotic aglycon derivs. could be ascribed to inhibition of the viral entry process.


IT 562105-47-9P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (antiretroviral activity of semisynthetic derivs. of glycopeptide antibiotics)
 RN 562105-47-9 CAPLUS
 CN Glycine, (2R)-2-[3-[4-[(2R)-2-carboxy-2-[(phenylmethoxy)carbonyl]amino]ethyl]-2-chlorophenoxy]-4,5-dihydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl-(.beta.R)-3-chloro-.beta.-hydroxy-L-tyrosyl-, 4-methyl ester, cyclic (15.fwdarw.34)-ether, cyclic 22,42-[4,6,6'-trihydroxy-5-[(tricyclo[3.3.1.1^{3,7}]dec-2-ylamino)methyl][1,1'-biphenyl]-3',2-diyl] deriv., [2(2R),4(2S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 562105-30-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antiretroviral activity of semisynthetic derivs. of glycopeptide antibiotics)
 RN 562105-30-0 CAPLUS
 CN Ristomycin A aglycone, 38-[[[(6-aminohexyl)amino]carbonyl]-22,31-dichloro-41-[[[3-(decyldimethylammonio)propyl]amino]methyl]-38-de(methoxycarbonyl)-7-demethyl-19-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 2-A



REFERENCE COUNT:

39

THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

BROAD STRUCTURE + AIDS/HIV

=>

=> => fil reg; d stat que 18; fil cap1; d que nos 118; s 118 not 145

FILE 'REGISTRY' ENTERED AT 13:09:22 ON 12 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2007 HIGHEST RN 946658-01-1

DICTIONARY FILE UPDATES: 11 SEP 2007 HIGHEST RN 946658-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>.


L4

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L4.str



chain nodes :

31 32 40 45 46 47

ring nodes :

```

1  2  3  4  5  6  7  8  9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44
ring/chain nodes :
34 35
chain bonds :
10-46 19-31 21-32 25-47 38-40 41-45
ring/chain bonds :
11-34 15-34 18-35 24-26 28-36
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 25-26 25-30 26-27 27-28 28-29 29-30 36-37 36-41 37-38 38-39 41-42
42-43 43-44
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 24-26 25-47 28-
36 36-37 36-41 37-38 38-39 38-40 41-42 41-45 42-43 43-44
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30

```

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS

```

L8 7166 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 7940 ITERATIONS
 SEARCH TIME: 00.00.01

7166 ANSWERS

FILE 'CAPLUS' ENTERED AT 13:09:22 ON 12 SEP 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP.USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Sep 2007 VOL 147 ISS 12
 FILE LAST UPDATED: 11 Sep 2007 (20070911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L4 STR
L8 7166 SEA FILE=REGISTRY SSS FUL L4
L9 8578 SEA FILE=CAPLUS ABB=ON L8
L11 40388 SEA FILE=CAPLUS ABB=ON HUMAN IMMUNODEFICIENCY VIRUS+NT/CT
L13 20238 SEA FILE=CAPLUS ABB=ON ANTI-AIDS AGENTS/CT
L14 21658 SEA FILE=CAPLUS ABB=ON "AIDS (DISEASE)" +OLD/CT
L16 5597 SEA FILE=CAPLUS ABB=ON L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

L18 29 SEA FILE=CAPLUS ABB=ON L16 AND (L11 OR L13 OR L14)

L46 28 L18 NOT L45

=> d ibib abs hitind hitstr l46 1-28

L46 ANSWER 1 OF 28. CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1256641 CAPLUS Full-text
DOCUMENT NUMBER: 146:50262
TITLE: Antibiotic kit and compositions
INVENTOR(S): Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir
PATENT ASSIGNEE(S): Foamix Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006269485	A1	20061130	US 2006-448490	20060607 <--
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024 <--
WO 2004037225	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005069566	A1	20050331	US 2004-911367	20040804
US 2006140984	A1	20060629	US 2005-532618	20051222 <--
WO 2007099396	A2	20070907	WO 2006-IB3975	20060607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,				

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD,
 SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
 VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2002-429546P P 20021129 <--
 US 2003-492385P P 20030804
 WO 2003-IB5527 W 20031024
 US 2004-911367 A2 20040804
 US 2005-688244P P 20050607
 US 2005-532618 A2 20051222
 IL 2002-152486 A 20021025 <--

AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition

INCL 424045000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 62

IT AIDS (disease)

Acne

Actinoplanes

Allergy inhibitors

Allium sativum

Anesthetics

Anti-inflammatory agents

Antibacterial agents

Antibiotics

Antioxidants

Antitumor agents

Antiviral agents

Arctium

Aspergillus flavus

Bacillus (bacterium genus)

Barosma

Beeswax

Buffers

Burn

Camellia sinensis

Containers

Cordyceps sinensis

Dermatitis

Ear, disease

Echinacea

Elytrigia repens

Escherichia coli

Faenia interjecta

Foams

Fungicides

Gelation agents

Human
 Human papillomavirus
 Humulus
 Hydrophile-lipophile balance value
 Hypericum perforatum
 Immunomodulators
 Immunosuppressants
 Lavandula
 Maytenus aquifolium
 Maytenus evonymoides
 Maytenus ilicifolia
 Micromonospora
 Mycosis
 Neoplasm
 Nonsteroidal anti-inflammatory drugs
 Nose, disease
 Osteoarthritis
 Oxidizing agents
 Parasitocides
 Perilla
 Permeation enhancers
 Phaeoramularia
 Photodynamic therapy
 Plantago
 Polar solvents
 Propellants (sprays and foams)
 Pseudomonas
 Putterlickia pyracantha
 Putterlickia retrospinoso
 Putterlickia verrucosa
 Radical scavengers
 Respiratory system, disease
 Rumex crispus
 Skin, disease
 Skin-lightening cosmetics
 Streptomyces
 Streptomyces arenae
 Streptomyces refuineus
 Surfactants
 Sweat
 Syphilis
 Terfezia clavervii
 Thistle
 Thyme
 Trifolium pratense
 Tuberculostatics
 Ulcer
 Vagina, disease
 Wart
 Wound
 Wound healing promoters
 Zalerion arboricola
 (antibiotic kit and compns.)

IT 50-21-5, Lactic acid, biological studies 50-59-9, Cefaloridine
 50-70-4, Sorbitol, biological studies 50-76-0, Dactinomycin 50-81-7,
 Vitamin C, biological studies 50-81-7D, Vitamin C, derivs. 53-79-2,
 Puromycin 56-75-7, Chloramphenicol 56-81-5, Glycerol, biological
 studies 56-95-1, Chlorhexidine acetate 57-10-3, Hexadecanoic acid,
 biological studies 57-11-4, Stearic acid, biological studies 57-55-6,
 Propylene glycol, biological studies 57-62-5, Chlortetracycline

57-67-0, Sulfaguanidine 57-68-1, Sulfamethazine 57-92-1, Streptomycin
 57-92-1D, Streptomycin, derivs. 59-01-8, Kanamycin 59-40-5,
 Sulfaquinoxaline 60-54-8, Tetracycline 61-32-5, Meticillin 61-33-6,
 biological studies 61-57-4, Niridazole 61-72-3, Cloxacillin 63-74-1,
 Sulfanilamide 66-79-5, Oxacillin 66-81-9, Cycloheximide 68-26-8,
 Vitamin A 68-26-8D, Vitamin A, derivs. 68-35-9, Sulfadiazine
 68-41-7, Cycloserine 69-52-3, Ampicillin sodium 69-53-4, Ampicillin
 69-65-8, Mannitol 72-14-0, Sulfathiazole 79-14-1, Glycolic acid,
 biological studies 79-57-2, Oxytetracycline 80-08-0, Dapsone
 80-32-0, Sulfachlorpyridazine 80-35-3, Sulfamethoxypyridazine 80-74-0,
 Sulfisoxazole acetyl 83-88-5, Riboflavin, biological studies 85-73-4,
 Phthalylsulfathiazole 87-11-6, Thiolutin 94-36-0, Benzoyl peroxide,
 biological studies 98-88-4, Benzoyl chloride 106-14-9, 12-Hydroxy
 stearic acid 107-41-5, Hexylene glycol 108-46-3, Resorcinol,
 biological studies 108-95-2, Phenol, biological studies 110-17-8,
 Fumaric acid, biological studies 111-16-0, Pimelic acid 111-20-6,
 Sebacic acid, biological studies 111-90-0, Transcutol 112-85-6,
 Behenic acid 112-92-5, Stearyl alcohol 114-07-8, Erythromycin
 114-86-3, Phenformin 115-68-4, Sulfadiazine 115-77-5,
 Pentaerythritol, biological studies 116-43-8, Succinylsulfathiazole
 119-04-0, Framycetin 122-11-2, Sulfadimethoxine 123-99-9, Azelaic
 acid, biological studies 124-04-9, Adipic acid, biological studies
 125-46-2, Usnic acid 125-65-5, Pleuromutilin 126-07-8, Griseofulvin
 127-33-3, Demeclocycline 127-65-1 127-69-5, Sulfisoxazole 127-71-9,
 Sulfabenzamide 127-79-7, Sulfamerazine 128-46-1, Dihydrostreptomycin
 138-39-6, Mafenide 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole
 144-83-2, Sulfapyridine 147-52-4, Nafcillin 147-55-7, Phenethicillin
 152-47-6, Sulfalene 153-61-7, Cefalotin 154-21-2, Lincomycin
 303-81-1, Novobiocin 389-08-2, Nalidixic acid 443-48-1, Metronidazole
 468-28-0, Lupulone 479-98-1, Aucubin 488-04-0, Holomycin 497-72-3,
 Methymycin 503-83-3, Tetramic acid 505-48-6, Suberic acid 505-52-2,
 1,13-Tridecanedioic acid 506-30-9, Arachidic acid 506-48-9,
 Octacosanoic acid 510-18-9, Acetomycin 512-64-1, Echinomycin
 515-49-1, Sulfathiourea 515-64-0, Sulfisomidine 520-74-1, Agropyrene
 526-08-9, Sulfaphenazol 530-43-8, Chloramphenicol palmitate 532-31-0,
 Silver benzoate 534-16-7, Silver carbonate 539-35-5, Mycobacin
 539-86-6, Allicin 547-44-4, Sulfacarbamide 551-27-9, Propicillin
 551-92-8, Dimetridazole 563-63-3, Silver acetate 564-25-0, Doxycycline
 593-50-0, 1-Triacontanol 599-88-2, Sulfaperine 606-58-6, Vengicide
 629-96-9, Arachidyl alcohol 637-32-1, Proguanil hydrochloride 643-22-1
 , Erythromycin stearate 661-19-8, Behenyl alcohol 693-23-2,
 1,12-Dodecanedioic acid 723-46-6, Sulfamethoxazole 729-99-7,
 Sulfamoxole 738-70-5, Trimethoprim 738-72-7, Protomycin 751-97-3,
 Rolitetracycline 801-52-5, Porfiromycin 821-38-5, 1,14-
 Tetradecanedioic acid 914-00-1, Methacycline 982-57-0, Chloramphenicol
 succinate sodium 983-85-7, Penamycin 987-02-0, Demethyltetracycline
 992-21-2, Lymecycline 1018-71-9, Pyrrolnitrin 1066-17-7, Colistin
 1088-92-2, Nifurtinol 1115-70-4, Metformin hydrochloride 1161-88-2,
 Sulfatolamide 1181-54-0, Clomocycline 1190-53-0, Buformin
 hydrochloride 1220-83-3, Sulfamonomethoxine 1264-62-6, Erythromycin
 ethyl succinate 1314-13-2, Zinc oxide, biological studies 1314-23-4,
 Zirconium oxide, biological studies 1332-37-2, Iron oxide, biological
 studies 1391-41-9, Endomycin 1391-62-4, Fluvomycin 1392-21-8,
 Kitasamycin 1392-21-8D, Leucomycin, derivs. 1392-60-5, Mycosubtilin
 1393-12-0, Rimocidin 1393-38-0, Subtilin 1393-48-2, Thiostrepton
 1393-68-6, Botromycin 1393-87-9, Fusafungin 1394-02-1, Hachimycin
 1395-21-7, Bacillomycin 1397-84-8, Alazopeptin 1400-61-9, Nystatin
 1401-63-4, Thioaurin 1401-69-0, Tylosin 1402-38-6, Actinomycin
 1402-82-0, Amfomycin 1402-83-1, Angolamycin 1402-88-6, Ascocin
 1403-17-4, Candicidin 1403-61-8, Fradycin 1403-66-3, Gentamicin

1403-71-0, Hamycin 1403-95-8, Mediocidin 1403-95-8D, Mediocidin, Me
 derivs. 1404-04-2, Neomycin 1404-08-6, Neutramycin 1404-26-8,
 Polymyxin B 1404-55-3, Ristocetin 1404-63-3, Sistomycosin 1404-74-6,
 Streptovaricin 1404-88-2, Tyrothricin 1404-90-6, Vancomycin
 1404-90-6D, Vancomycin, demethyl derivs. 1405-33-0, Angustmycin
 1405-41-0, Gentamycin sulfate 1405-87-4, Bacitracin 1405-97-6,
 Gramicidin 1406-11-7, Polymyxin 1406-16-2, Vitamin D 1406-16-2D,
 Vitamin D, derivs. 1406-18-4, Vitamin E 1414-39-7, Albomycin
 1414-45-5, Nisin 1438-30-8, Netropsin 1695-77-8, Spectinomycin
 1724-02-3D, Pentenedioic acid, derivs. 1852-04-6, Undecanedioic acid
 1926-49-4, Clometocillin 2001-95-8, Valinomycin 2013-58-3,
 Meclocycline 2022-85-7, Flucytosine 2079-00-7, Blastocidin S
 2086-83-1, Berberine 2096-42-6, Gougerotin 2134-29-4, Reuterin
 2447-57-6, Sulfadoxine 2520-21-0, Celesticetin 2750-76-7, Rifamide
 2751-09-9, Troleandomycin 2885-39-4, Acetoxycycloheximide 3116-76-5,
 Dicloxacillin 3366-95-8, Secnidazole 3485-14-1, Ciclacillin
 3508-01-8, Silver palmitate 3511-16-8, Hetacillin 3521-62-8,
 Erythromycin estolate 3545-49-1 3563-14-2, Sulfasuccinamide
 3689-76-7, Chlormidazole 3697-42-5, Chlorhexidine hydrochloride
 3847-29-8, Erythromycin lactobionate 3922-90-5, Oleandomycin
 3930-19-6, Streptonigrin 4107-73-7, Sulfatriazine 4117-65-1,
 Aspartocin 4135-11-9, Polymyxin B1 4564-87-8, Carbomycin 4572-56-9,
 Bromotetracycline 4682-50-2, Trichodermin 4696-76-8, Bekanamycin
 4697-36-3, Carbenicillin 4800-94-6, Carbenicillin disodium 4803-27-4,
 Anthramycin 5250-39-5, Flucloxacillin 5306-85-4, Dimethyl isosorbide
 5490-27-7, Dihydrostreptomycin sulfate 5636-92-0, Picloxydine
 6377-18-0, Chartreusin 6379-56-2, Hygromycin 6489-97-0, Metampicillin
 6506-37-2, Nimorazole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibiotic kit and compns.)

IT 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 72615-20-4, Bactobolin
 73090-70-7, Epiroprim 73151-29-8, Fenticonazole nitrate 73196-97-1,
 Dactimicin 73231-34-2, Florfenicol 73341-71-6, Oudemansin
 73384-59-5, Ceftriaxone 73816-42-9, Meclocycline sulfosalicylate
 73904-91-3, Microcin 74011-58-8, Enoxacin 74014-51-0, Rokitamycin
 74298-63-8, Chlormidazole hydrochloride 74352-51-5 74352-52-6
 74352-53-7 74352-54-8 74469-00-4, Amoxicillin-potassium clavulanate
 mixture 74497-04-4, Oxolonomycin 74512-12-2, Omoconazole 74758-63-7,
 Alanylclavam 74913-06-7, Chromomycin 75060-25-2, 3-Trehalosamine
 75081-92-4, Epihygromycin 75433-48-6, Herbicolin 75635-18-6,
 Seldomycin 75635-19-7, Sorbistin 76157-50-1, Chlorocarcin 76260-86-1
 76363-52-5, Cytophagin 76448-31-2, Propenidazole 76470-66-1,
 Loracarbef 76610-84-9, Cefbuperazone 76631-42-0, Nocardicin
 76774-97-5, Istamycin 76828-82-5, Dnacin 77174-66-4 77175-51-0,
 Croconazole 77312-55-1 77312-57-3 77378-01-9 77398-03-9,
 3-O-Demethylistamycin B 77550-86-8, Northienamycin 77642-19-4,
 Stubomycin 77904-47-3, Juvenimicin 78040-85-4, Coumermycin
 78110-38-0, Aztreonam 78308-34-6, Neoviridogrisein 78565-33-0,
 Tridecaptin 78874-50-7 78874-51-8 78874-52-9 78874-53-0
 78874-54-1 78922-09-5, Baumycin 79350-37-1, Cefixime 79392-34-0,
 Saframycin 79404-91-4, Cilofungin 79548-73-5, Pirlimycin 79620-36-3,
 Candiplanecin 79660-72-3, Fleroxacin 80209-40-1, Fragilomycin
 80210-62-4, Cefpodoxime 80214-83-1, Roxithromycin 80394-72-5,
 Oxanosine 80449-89-4, Kristenin 80621-81-4, Rifaximin 80890-47-7,
 Concanamycin 81103-11-9, Clarithromycin 81202-83-7 81661-90-7,
 5-O-Mycaminosyltylactone 81774-69-8, Polynitroxin 81831-80-3,
 Trioxacarcin 82419-36-1, Ofloxacin 82547-58-8, Cefteteram 82547-81-7,
 Cefteteram pivoxil 82664-20-8, Flurithromycin 82854-37-3, Echinacoside
 83198-27-0, Saphenamycin 83905-01-5, Azithromycin 84305-41-9, Cefminox
 84420-34-8, Paromomycin 84625-61-6, Itraconazole 84957-29-9, Cefpirome

84957-30-2, Cefquinome 85721-33-1, Ciprofloxacin 86003-55-6,
 Nikkomycin 86258-26-6, 3-Demethoxyistamycin B 86273-18-9,
 Lenampicillin 86386-73-4, Fluconazole 86408-37-9, Isohematinic acid
 86596-26-1, Trestatin 86630-31-1, Saccharocin 86630-31-1D,
 Saccharocin, derivs. 87099-85-2, Spicamycin 87239-81-4, Cefpodoxime
 proxetil 87385-18-0, Ditrisarubicin C 87638-04-8, Carumonam
 87726-17-8, Panipenem 87913-35-7, Awamycin 87915-59-1, Lankacidin
 88026-21-5, Leptomycin 88040-23-7, Cefepime 88205-90-7, Oxirapentyn
 88465-80-9, Arugomycin 88507-21-5, Staphylocidin 89139-42-4,
 Teicoplanin aglycone 89156-94-5, Akrobomycin 89699-33-2,
 Fosfonochlorin 89786-04-9, Tazobactam 90092-49-2, Clazamycin
 91832-40-5, Cefdinir 92090-94-3, Kazusamycin 92665-29-7, Cefprozil
 93106-60-6, Enrofloxacin 93107-08-5, Ciprofloxacin hydrochloride
 93908-02-2, Rebeccamycin 94116-22-0, Guanidylfungin A 94593-72-3,
 Serirubicin 94935-63-4, Ampicillinsulbactam 95041-97-7, Acimycin
 95660-15-4, Chloropolysporin 96036-03-2, Meropenem 97519-39-6,
 Ceftibuten 98079-51-7, Lomefloxacin 98079-52-8, Lomefloxacin
 hydrochloride 99592-32-2, Sertaconazole 99592-39-9, Sertaconazole
 nitrate 99665-00-6, Flomoxef 100044-27-7, Bagacidin 100440-25-3,
 Terpentecin 100490-36-6, Tosufloxacin 100940-65-6, Sandramycin
 100986-85-4, Levofloxacin 101363-10-4, Rufloxacin 101530-10-3,
 Lanoconazole 101670-43-3, Humidin 102418-10-0, Selenomycin
 102646-78-6, Libanomycin A 102732-36-5, Hydropricin 102732-37-6,
 Oxypricin 102903-07-1, Antrimycin 102961-92-2, Corallopyronin
 103060-53-3, Daptomycin 103358-10-7 103972-98-1 104145-95-1,
 Cefditoren 104486-81-9, Mupirocin calcium 104987-11-3, Tacrolimus
 104987-12-4, Ascomycin 106486-76-4, Carzinophilin 106560-14-9,
 Faropenem 108050-54-0, Tilmicosin 108065-99-2, Globopeptin
 108319-06-8, Temafloxacin 108351-50-4, Glidobactin 110231-33-9,
 Fumifungin 110871-86-8, Sparfloxacin 111092-67-2, Nanaomycin
 111643-99-3, Tejeramycin 111839-55-5, Nargenicin 112008-27-2,
 Swalpamycin 112354-01-5, Xylocandin 112398-08-0, Danofloxacin
 112811-59-3, Gatifloxacin 113041-69-3, Magainin 113285-19-1, Etamycin
 113359-04-9, Cefozopran 113441-12-6, Primycin 113617-63-3,
 Orbifloxacin 114797-28-3, Esperamicin 117184-53-9, Aranorosin
 117192-99-1, Boholmycin 117467-28-4, Cefditoren pivoxil 117541-57-8,
 Rhizocticin 118374-47-3, Lysobactin 118498-90-1, Unphenelfamycin
 119006-77-8, Flutrimazole 119914-60-2, Grepafloxacin 120410-24-4,
 Biapenem 120500-15-4, Leinamycin 121634-34-2 121634-35-3
 122301-98-8, Vermisporin 122841-10-5, Cefoselis 123997-21-7, Apidaecin
 124759-75-7, Dynemicin 124759-75-7D, Dynemicin, derivs. 124858-35-1,
 Nadifloxacin 125213-21-0, Culpin 126602-89-9, Quinupristin-
 dalfopristin 127045-41-4, Pazufloxacin 127999-44-4, Tolytoxin
 128104-18-7, Mersacidin 128808-89-9, Orthosomycin 129428-69-9,
 Megalomycin 130726-68-0, Neticonazole 132605-69-7, Butalactin
 135889-00-8, Cefcapene 136398-54-4, Alisamycin 137234-62-9,
 Voriconazole 138626-63-8, Deoxymulundocandin 139638-79-2, Sperabillin
 140932-79-2, Balhimycin 141363-91-9, Lanomycin 143383-65-7,
 Premafloxacin 145269-73-4, Neopeptifluorin 145269-84-7, Peptifluorin
 146961-76-4, Alatrofloxacin 147059-72-1, Trovafloxacin 147816-23-7,
 Cefcapene pivoxil hydrochloride 148717-90-2, Squalamine 151096-09-2,
 Moxifloxacin 151499-39-7, Bafilomycin 151581-81-6, Pradimicin
 153832-46-3, Ertapenem 160674-34-0, Bacillaene 162808-62-0,
 Caspofungin 175463-14-6, Gemifloxacin 178234-32-7, Acetylkitasamycin
 178330-12-6, Ascosteroside 178694-47-8, Focusin 191114-48-4,
 Telithromycin 199169-60-3, Corynecandin 344362-08-9, Amycomycin
 436813-45-5, Conioisetin 682351-48-0, Benanomycin 808103-38-0,
 Cepacidine 916322-17-3 916322-18-4 916322-19-5 916322-20-8
 916322-23-1 916322-25-3 916322-28-6 916328-91-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibiotic kit and compns.)

IT 1404-90-6, Vancomycin 1404-90-6D, Vancomycin, demethyl
derivs. 89139-42-4, Teicoplanin aglycone 140932-79-2,
Balhimycin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibiotic kit and compns.)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i


PAGE 2-A



RN 1404-90-6 CAPLUS
 CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

— Bu-i

PAGE 2-A




RN 89139-42-4 CAPLUS


CN Ristomycin A aglycone, 22,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy-
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A



PAGE 3-A




PAGE 4-A




RN 140932-79-2 CAPLUS
 CN Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl- α -L-threo-hexopyranos-4-ulos-1-yl)-2'-O-de(3-amino-2,3,6-trideoxy-3-C-methyl- α -L-lyxo-hexopyranosyl)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L46 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:485575 CAPLUS Full-text

DOCUMENT NUMBER: 143:32218

TITLE: Sustained-release biodegradable microcapsules for delivery of anti-infective agents in the treatment and prevention of infections

INVENTOR(S): Setterstrom, Jean A.; Tice, Thomas R.; Jacob, Elliot; Reid, Robert H.; Van Hamont, John; Boedecker, Edgar C.; Jeyanthi, Ramassubbu; Friden, Phil; Roberts, F. Donald; McQueen, Charles E.; Bhattacharjee, Apurba; Cross, Alan; Sadoff, Jerald; Zollinger, Wendell

PATENT ASSIGNEE(S): The United States of America as Represented by the
 Secretary of the Army, USA
 SOURCE: U.S., 167 pp., Cont.-in-part of U.S. Ser. No. 920,326.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 17
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6902743	B1	20050607	US 1998-55505	19980406 <--
US 6410056 ✓	B1	20020625	US 1995-446148	19950522 <--
US 5762965 ✓	A	19980609	US 1996-598874	19960209 <--
US 6217911	B1	20010417	US 1996-675895	19960705 <--
US 5705197	A	19980106	US 1996-698896	19960816 <--
NZ 335409	A	20001222	NZ 1996-335409	19961118 <--
US 6447796 ✓	B1	20020910	US 1997-920326	19970821 <--
US 7033608	B1	20060425	US 1999-337945	19990622 <--
PRIORITY APPLN. INFO.:			US 1995-446148	A2 19950522 <--
			US 1995-446149	B1 19950522 <--
			US 1996-590973	B2 19960124 <--
			US 1996-598874	A2 19960209 <--
			US 1996-675895	A2 19960705 <--
			US 1996-698896	A2 19960816 <--
			US 1997-788734	A2 19970123 <--
			US 1997-896197	B2 19970717 <--
			US 1997-920326	A2 19970821 <--
			US 1984-590308	B2 19840316 <--
			US 1990-493597	B2 19900315 <--
			US 1990-521945	B2 19900511 <--
			US 1991-690485	B2 19910424 <--
			US 1991-805721	B2 19911121 <--
			US 1992-867301	A2 19920410 <--
			US 1994-209350	B2 19940107 <--
			US 1994-242960	A2 19940516 <--
			NZ 1996-325561	A1 19961118 <--
			US 1997-789734	A2 19970127 <--
AB	Novel burst-free, sustained release biocompatible and biodegradable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiol. environment. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.			
IC	ICM A61K009-14 ICS A61K039-40; A61K009-48; A61K009-26; A61K009-16			
INCL	424489000; 424177000; 424179000; 424451000; 424470000; 424482000; 424490000			
CC	63-5 (Pharmaceuticals) Section cross-reference(s): 1, 15			
IT	Acinetobacter Actinobacillus Actinomyces Actinomycetales Aerobacter Aerococcus Aeromonas Arbovirus			

Arcanobacterium haemolyticum
Arenavirus
Bacilli
Bacteroides
Bordetella
Borrelia
Brucella
Calymatobacterium
Campylobacter
Campylobacter fetus
Clostridium
Coronavirus
Corynebacterium
Cytomegalovirus
Cytophaga
Ebola virus
Enterobacter aerogenes
Enterobacteriaceae
Enterococcus
Enterovirus
Erysipelothrix
Escherichia coli
Filovirus
Flavobacterium
Fusobacterium
Gardnerella
Gemella
Gram-negative bacteria
Gram-positive bacteria
Haemophilus
Helicobacter
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Human adenovirus
Human herpesvirus
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human herpesvirus 5
Human immunodeficiency virus
Human parainfluenza virus
Human poliovirus
Influenza virus
Klebsiella
Lactococcus
Legionella
Legionella pneumophila
Leptospira
Leuconostoc
Listeria
Measles virus
Micrococcus
Moraxella
Morganella morganii
Mumps virus
Mycobacterium
Mycoplasma
Neisseria

Neisseria meningitidis
 Papillomavirus
 Parasite
 Pasteurella
 Pediococcus
 Peptococcus
 Peptostreptococcus
 Planococcus (bacterium)
 Plesiomonas
 Polyomavirus
 Poxviridae
 Propionibacterium
 Proteus (bacterium)
 Proteus vulgaris
 Pseudomonas
 Rabies virus
 Reoviridae
 Respiratory syncytial virus
 Rhinovirus
 Rhodococcus
 Rotavirus
 Rothia (bacterium)
 Rubella virus
 Salmonella typhi
 Shigella boydii
 Shigella dysenteriae
 Shigella flexneri
 Shigella sonnei
 Spirillum
 Staphylococcus
 Staphylococcus aureus
 Streptobacillus
 Streptococcus
 Streptococcus pyogenes
 Treponema
 Vibrio
 Vibrio cholerae
 Wolinella succinogenes
 Yersinia

(infection by, treatment and prevention of; sustained-release
 biodegradable microcapsules for delivery of anti-infective agents in
 treatment and prevention of infections)

IT 56-75-7, Chloramphenicol 59-01-8, Kanamycin 59-87-0 61-33-6,
 biological studies 114-07-8, Erythromycin 288-32-4D, Imidazole,
 antibiotic derivs. 443-48-1 738-70-5, Trimethoprim 751-94-0
 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-26-8, Polymyxin B
 1404-90-6, Vancomycin 11111-12-9, Cephalosporin 13292-46-1,
 Rifampin 32986-56-4, Tobramycin 37517-28-5, Amikacin 61036-62-2,
 Teicoplanin 78110-38-0, Aztreonam 80738-43-8, Lincosamide
 92309-29-0, Imipenem-cilastatin-mixture

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (delivery of; sustained-release biodegradable microcapsules for
 delivery of anti-infective agents in treatment and prevention of
 infections)

IT 1404-90-6, Vancomycin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (delivery of; sustained-release biodegradable microcapsules for
 delivery of anti-infective agents in treatment and prevention of
 infections)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:430954 CAPLUS Full-text
DOCUMENT NUMBER: 141:1204
TITLE: Antimicrobial activity of antibodies producing
reactive oxygen species
INVENTOR(S): Wentworth, Paul; Lerner, Richard A.
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.; The
Scripps Research Institute
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004044191	A1	20040527	WO 2003-EP12709	20031113 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2505932	A1	20040527	CA 2003-2505932	20031113 <--
AU 2003288057	A1	20040603	AU 2003-288057	20031113 <--
EP 1563062	A1	20050817	EP 2003-779919	20031113 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016245	A	20051004	BR 2003-16245	20031113 <--
CN 1738898	A	20060222	CN 2003-80108716	20031113 <--
JP 2006506419	T	20060223	JP 2004-551019	20031113 <--
US 2007009537	A1	20070111	US 2005-534575	20050511 <--
PRIORITY APPLN. INFO.:			US 2002-426242P	P 20021114 <--
			WO 2003-EP12709	W 20031113

AB The invention provides compns. having antibodies that can generate reactive oxygen species when exposed to singlet oxygen, as well as methods of using the compns., for example, to treat microbial infections. The invention provides methods for utilizing newly discovered abilities of antibodies to produce reactive oxygen species. Hydrogen proxyde production mediated by Igs was demonstrated. It was also demonstrated, that antibodies catalyze the oxidation of water. According to the invention, antibodies can kill microbes by converting singlet oxygen into reactive oxygen species. Reactive oxygen species generated by the antibodies of the invention include superoxide radicals, hydroxyl radicals, hydrogen peroxide, ozone and other reactive oxygen species. Thus, the invention is directed to an anti-microbial composition consisting essentially of a pharmaceutically acceptable carrier and an isolated antibody that can bind to a microbe, wherein the antibody can generate a reactive oxygen species when singlet oxygen is present. The anti-microbial composition can also contain a sensitizer mol. that can generate singlet oxygen. Examples of sensitizer mol. include a pterin, a flavin, a hematoporphyrin, a tetrakis (4-sulfonatophenyl) porphyrin, a bipyridyl ruthenium (II) complex, a rose Bengal dye, a quinone, a rhodamine dye, a

phthalocyanine, a hypocrellin, rubrocyanine, pinacyanol, allocyanine or a chlorin.

IC ICM C12N009-00
ICS A61P031-04; A61P031-12; C07K016-12; C07K016-08

CC 1-5 (Pharmacology)
Section cross-reference(s): 7; 15, 63

IT Adenoviridae
Aeromonas
Alphavirus
Antibacterial agents
Antimicrobial agents
Antiviral agents
Arenavirus
Bacillus (bacterium genus)
Bacteroides
Bunyavirus
Burkholderia cepacia
Campylobacter
Cholera
Clostridium
Coronavirus
DNA viruses
Diarrhea
Enterobacter
Enterococcus
Enterococcus faecalis
Enterococcus faecium
Enterovirus
Escherichia
Escherichia coli
Filovirus
Flavivirus
Food poisoning
Gastrospirillum
Gram-negative bacteria
Helicobacter
Helicobacter pylori
Hepadnaviridae
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Herpesviridae
Human immunodeficiency virus
Influenza A virus
Influenza B virus
Klebsiella
Lyssavirus
Morbillivirus
Nairovirus
Orbivirus
Orthomyxovirus
Papovaviridae
Paramyxovirus
Parvovirus
Phlebovirus
Picornaviridae
Pneumonia
Pneumovirus
Poxviridae
Prion diseases

Pseudomonas
 Pseudomonas aeruginosa
 RNA viruses
 Reoviridae
 Retroviridae
 Rhabdoviridae
 Rhinovirus
 Rotavirus
 Rubivirus
 Salmonella
 Salmonella typhi
 Salmonella typhimurium
 Shigella
 Shigella dysenteriae
 Staphylococcus
 Staphylococcus aureus
 Ulcer
 Vibrio
 Vibrio cholerae
 Viroid
 Yersinia

(antimicrobial activity of antibodies producing reactive oxygen species)

IT 1404-90-6, Vancomycin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (bacteria with resistance to; antimicrobial activity of antibodies producing reactive oxygen species)

IT 1404-90-6, Vancomycin


RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (bacteria with resistance to; antimicrobial activity of antibodies producing reactive oxygen species)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:182718 CAPLUS Full-text
 DOCUMENT NUMBER: 140:241007
 TITLE: Multifunctional context-activated protides and methods of use
 INVENTOR(S): Yeaman, Michael R.; Yount, Nannette Y.; Edwards, John E., Jr.; Brass, Eric P.
 PATENT ASSIGNEE(S): Harbor-UCLA Research and Education Institute, USA
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017985	A1	20040304	WO 2003-US26405	20030820 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006074016 A1 20060406 US 2002-225562 20020820 <--
 US 7067621 B2 20060627
 AU 2003274919 A1 20040311 AU 2003-274919 20030820 <--
 US 2006135416 A1 20060622 US 2005-524952 20050218 <--

PRIORITY APPLN. INFO.:

US 2002-225562 A 20020820 <--
 WO 2003-US26405 W 20030820

AB This invention is directed to multifunctional, context-activated protides that have two or more effectors with individually distinct biol. functions and one or more corresponding activator sites that can each initiate or amplify the biol. function of one or more effectors upon context-activation. The context-activated protides of the invention are useful in the diagnosis, prophylaxis, and therapy of a broad range of pathol. conditions.

IC ICM A61K038-00

CC 63-5 (Pharmaceuticals)

IT Human immunodeficiency virus

(viral protein R of; multifunctional context-activated protides and methods of use)

IT 61-32-5, Methicillin 1404-90-6, Vancomycin

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(-resistant Staphylococcus aureus; multifunctional context-activated protides and methods of use)

IT 1404-90-6, Vancomycin

RL: BSU (Biological study, unclassified); BIOL (Biological study)


(-resistant Staphylococcus aureus; multifunctional context-activated protides and methods of use)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:80343 CAPLUS Full-text

DOCUMENT NUMBER: 140:122836

TITLE: Use of 2,3-alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals

INVENTOR(S): Stec, Karen; Rubinstein, Israel; Eiznhamer, David; Xu, Ze-qu; Flavin, Michael

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 6 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004019022	A1	20040129	US 2003-622302	20030718 <--
WO 2004010989	A1	20040205	WO 2003-US23644	20030718 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003252178 A1 20040216 AU 2003-252178 20030718 <--
 EP 1539132 A1 20050615 EP 2003-772019 20030718 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPLN. INFO.: US 2002-398523P P 20020725 <--
 WO 2003-US23644 W 20030718

AB A method for the treatment of cellular and tissue damage is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof for the prevention and treatment of dysfunction, damage, and/or injuries to organs, tissues and/or cells in human or animal subjects caused by diseases, infections and conditions such as pneumonia, coronavirus, multiple transfusions, trauma, ischemic-reperfusion dysfunctions, stroke, drug overdose, and severe acute respiratory syndrome. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics. The acid may be administered in any practical delivery form, and in free acid or buffered form.

IC ICM A61K038-12
 ICS A61K038-00; A61K038-16; A61K031-704; A61K031-60; A61K031-496
 INCL 514159000; 514008000; 514192000; 514034000; 514252130; 514029000;
 514002000; 514253080; 514312000

CC 1-12 (Pharmacology)
 Section cross-reference(s): 2, 4, 10, 63

IT AIDS (disease)
 Acinetobacter
 Acne
 Alcoholism
 Alzheimer's disease
 Anti-AIDS agents
 Anti-Alzheimer's agents
 Antibacterial agents
 Antibiotics
 Antihypotensives
 Antiparkinsonian agents
 Antiviral agents
 Arthritis
 Asthma
 Atherosclerosis
 Brain, disease
 Chlamydia pneumoniae
 Cirrhosis
 Coronavirus
 Cystic fibrosis
 Diabetes mellitus
 Drug interactions
 Emphysema
 Encephalitis
 Enterococcus
 Escherichia coli
 Haemophilus influenzae
 Hemochromatosis
 Hepatitis
 Human
 Human adenovirus

Human herpesvirus 4
 Human immunodeficiency virus
 Human immunodeficiency virus 1

Human metapneumovirus

Human parainfluenza virus

Immunomodulators

Injury

Klebsiella pneumoniae

Lung

Lupus erythematosus

Lyme disease

Meningitis

Multiple sclerosis

Mycobacterium

Mycobacterium avium

Mycobacterium tuberculosis

Mycoplasma pneumoniae

Mycosis

Neutrophil

Paramyxovirus

Parkinson's disease

Platelet aggregation inhibitors

Pneumonia

Poisoning, biological

Preeclampsia

Preeclampsia

Prion diseases

Pseudomonas aeruginosa

Psoriasis

Respiratory syncytial virus

Rheumatoid arthritis

Rhinovirus

Sarcoidosis

Sepsis

Staphylococcus aureus

Streptococcus

Streptococcus pneumoniae

Surgery

Thrombolytics

Thrombus

Transplant and Transplantation

β -Adrenoceptor agonists

(use of alkylcarbonyloxybenzoic acids, derivs. and analogs therefrom
 for treatment of tissue and cellular dysfunction, damage and injury in
 mammals)

IT 51-61-6, Dopamine, biological studies 52-67-5, Penicillamine 56-75-7,
 Chloramphenicol 58-32-2, Dipyridamole 64-86-8, Colchicine 65-85-0D,
 Benzoic acid, alkylcarbonyloxy derivs. and sodium salts 70-51-9,
 Desferrioxamine 486-79-3, 2,3-Diacetoxybenzoic acid 564-25-0,
 Doxycycline 1403-66-3, Gentamicin 1404-90-6, Vancomycin
 1406-05-9, Penicillin 9002-01-1, Streptokinase 9039-53-6, Urokinase
 9041-92-3, Prolastin 13292-46-1, Rifampin 18323-44-9, Clindamycin
 36791-04-5, Ribavirin 64221-86-9, Imipenem 65277-42-1, Ketoconazole
 81103-11-9, Clarithromycin 81669-57-0, Anistreplase 84625-61-6,
 Itraconazole 86386-73-4, Fluconazole 98530-76-8, Drotrecogin alfa
 (activated) 105857-23-6, Alteplase 113665-84-2, Clopidogrel
 126602-89-9, Quinupristin/dalfopristin 133652-38-7, Reteplase
 139639-23-9, Tissue plasminogen activator 165800-03-3, Linezolid
 191588-94-0, Tenecteplase

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(use of alkylcarbonyloxybenzoic acids, derivs. and analogs therefrom
for treatment of tissue and cellular dysfunction, damage and injury in
mammals)

IT 1404-90-6, Vancomycin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(use of alkylcarbonyloxybenzoic acids, derivs. and analogs therefrom
for treatment of tissue and cellular dysfunction, damage and injury in
mammals)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



L46 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:41226 CAPLUS Full-text

DOCUMENT NUMBER: 140:105321

TITLE: Methods and compositions relating to isoleucine boroproline compounds

INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry

PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 152 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709 <--
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491466	A1	20040115	CA 2003-2491466	20030709 <--
AU 2003265264	A1	20040123	AU 2003-265264	20030709 <--
US 2004077601	A1	20040422	US 2003-616694	20030709 <--
US 2005084490	A1	20050421	US 2003-616409	20030709 <--
EP 1578434	A2	20050928	EP 2003-763380	20030709 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507352	T	20060302	JP 2004-562634	20030709 <--
CN 1802090	A	20060712	CN 2003-821282	20030709 <--

CN 1826129	A	20060830	CN 2003-821281	20030709 <--
IN 2005KN00151	A	20050916	IN 2005-KN151	20050208 <--
PRIORITY APPLN. INFO.:			US 2002-394856P	P 20020709 <--
			US 2002-414978P	P 20021001 <--
			US 2003-466435P	P 20030428
			WO 2003-US21405	W 20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, $\text{AmNHCH}(\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3)\text{COA1R}$) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptidyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α -aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

IC ICM A61K

CC 1-12 (Pharmacology)

Section cross-reference(s): 15

IT Actinomyces
 Adenoviridae
 Bacteroides
 Borrelia
 Campylobacter
 Citrobacter
 Clostridium difficile
 Corynebacterium
 Cytomegalovirus
 Echinococcus
 Enterobacter
 Escherichia coli
 Fasciola
 Gardnerella
 Haemophilus
 Helicobacter pylori
 Human herpesvirus 1
 Human herpesvirus 2
 Human herpesvirus 3
 Human herpesvirus 4
 Human immunodeficiency virus
 Human papillomavirus
 Hymenolepis
 Klebsiella
 Legionella
 Listeria
 Monkeypox virus
 Necator americanus
 Neisseria
 Nocardia
 Paragonimus
 Pasteurella
 Pneumocystis
 Proteus (bacterium)
 Pseudomonas
 Respiratory syncytial virus
 Rotavirus
 Salmonella
 Shigella

Spirillum
 Spirochaeta
 Streptobacillus
 Streptococcus
 Streptococcus pneumoniae
 Taenia
 Treponema
 Trichomonas vaginalis
 Trichuris trichiura
 Trypanosoma brucei
 Trypanosoma cruzi

(infection; therapeutic methods and compns. relating to isoleucine
 boroproline compds. alone or in combination with other drugs,
 antibodies, or antigens)

IT 50-18-0, Cyclophosphamide 50-44-2 50-59-9, Cephaloridine 50-63-5,
 Chloroquine phosphate 50-65-7, Niclosamide 50-76-0, Dactinomycin
 50-91-9, Floxuridine 51-21-8, Fluorouracil 52-68-6, Metrifonate
 53-03-2, Prednisone 54-42-2, Idoxuridine 54-85-3, Isoniazid 55-86-7,
 Mechlorethamine hydrochloride 56-75-7, Chloramphenicol 57-62-5,
 Chlortetracycline 57-68-1, Sulfamethazine 57-92-1, Streptomycin,
 biological studies 58-71-9, Cephalothin sodium 59-05-2, Methotrexate
 60-54-8, Tetracycline 61-32-5, Methicillin 63-45-6, Primaquine
 phosphate 64-72-2, Chlortetracycline hydrochloride 64-73-3,
 Demeclocycline hydrochloride 64-75-5, Tetracycline hydrochloride
 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 67-45-8, Furazolidone
 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-05-6, Quinacrine
 hydrochloride 69-52-3, Ampicillin sodium 69-53-4, Ampicillin
 69-57-8, Penicillin g sodium 69-74-9, Cytarabine hydrochloride
 70-00-8, Trifluridine 70-10-0, Ticlatone 72-14-0, Sulfathiazole
 74-55-5, Ethambutol 77-46-3, Acedapsone 79-57-2, Oxytetracycline
 80-08-0, Dapsone 80-74-0, Sulfisoxazole acetyl 83-73-8, Iodoquinol
 87-08-1, Penicillin v 88-04-0, Chloroxylenol 90-89-1,
 Diethylcarbamazine 97-18-7, Bithionol 98-96-4, Pyrazinamide
 100-97-0, Methenamine, biological studies 102-76-1, Triacetin 106-48-9
 110-85-0, Piperazine, biological studies 112-38-9, Undecylenic acid
 113-98-4, Penicillin g potassium 114-07-8, Erythromycin 115-02-6,
 Azaserine 121-19-7, Roxarsone 121-81-3, Nitromide 122-16-7,
 Sulfanitran 124-07-2, Octanoic acid, biological studies 126-07-8,
 Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline
 127-56-0, Sulfacetamide sodium 127-69-5, Gantrisin 127-71-9,
 Sulfabenzamide 127-77-5, Sulfabenz 127-79-7, Sulfamerazine 128-12-1,
 Acetosulfone sodium 130-16-5, Cloxyquin 132-92-3, Methicillin sodium
 132-98-9, Penicillin v potassium 133-10-8, p-Aminosalicylate sodium
 133-11-9, Phenyl aminosalicylate 133-51-7, Meglumine antimoniate
 134-36-1, Erythromycin propionate 137-26-8, Thiram 138-39-6, Mafenide
 140-64-7, Pentamidine isethionate 143-67-9, Vinblastine sulfate
 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 145-63-1, Suramin
 147-52-4, Nafcillin 147-94-4, Cytarabine 148-79-8, Thiabendazole
 148-82-3, Melphalan 152-47-6, Sulfalene 153-61-7, Cephalothin
 154-21-2, Lincomycin 288-32-4, Imidazole, biological studies
 288-32-4D, Imidazole, derivs. 305-03-3, Chlorambucil 343-55-5,
 Dicloxacillin sodium 366-70-1, Procarbazine hydrochloride 389-08-2,
 Nalidixic acid 443-48-1, Metronidazole 494-79-1, Melarsoprol
 500-92-5, Proguanil 527-75-3, Erythromycin 528-96-1, Benzoylpas
 calcium 530-43-8, Chloramphenicol palmitate 536-33-4, Ethionamide
 547-32-0, Sulfadiazine sodium 554-72-3, Tryparsamide 555-84-0,
 Nifuradene 557-08-4, Zinc undecyl enate 564-25-0, Doxycycline
 575-54-2, Penicillins 587-23-5, Methenamine mandelate 599-79-1,
 Sulfasalazine 632-00-8, Sulfasomizole 642-78-4, Cloxacillin sodium
 643-22-1, Erythromycin stearate 651-06-9, Sulfameter 665-66-7,

Amantadine hydrochloride 723-46-6, Sulfamethoxazole 729-99-7,
 Sulfamoxole 735-52-4, Cetophenicol 738-70-5, Trimethoprim 751-94-0,
 Fusidate sodium 751-97-3, Rolitetracycline 768-94-5, Amantadine
 777-11-7, Haloprogin 801-52-5, Porfiromycin 804-63-7, Quinine sulfate
 808-26-4, Sancycline 847-25-6, Racephenicol 852-19-7, Sulfazamet
 859-18-7, Lincomycin hydrochloride 909-14-8 914-00-1, Methacycline
 982-57-0, Chloramphenicol sodium succinate 983-85-7, Penamecillin
 985-16-0, Nafcillin sodium 987-02-0, Demecycline 1018-71-9,
 Pyrrolnitrin 1070-11-7, Ethambutol hydrochloride 1173-88-2, Oxacillin
 sodium 1220-83-3, Sulfamonomethoxine 1264-62-6, Erythromycin ethyl
 succinate 1264-72-8, Colistin sulfate 1322-14-1, Calcium undecylenate
 1336-20-5, Tetracycline phosphate complex 1392-21-8, Kitasamycin
 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1402-82-0, Amphomycin
 1403-17-4, Candicidin 1403-66-3, Gentamicin 1403-71-0, Hamycin
 1404-00-8, Mitomycin 1404-08-6, Neutramycin 1404-48-4, Relomycin
 1404-59-7, Rutamycin 1404-88-2, Tyrothricin 1404-90-6,
 Vancomycin 1404-93-9, Vancomycin hydrochloride 1405-00-1,
 Viridofulvin 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin b
 sulfate 1405-37-4, Capreomycin sulfate 1405-41-0, Gentamicin sulfate
 1405-52-3, Sulfomycin 1405-87-4, Bacitracin 1405-89-6, Bacitracin zinc
 1405-97-6, Gramicidin 1406-04-8, Neomycin undecyl enate 1406-11-7,
 Polymyxin 1432-75-3, Nitralamine hydrochloride 1476-53-5, Novobiocin
 sodium 1501-84-4, Rimantadine hydrochloride 1538-09-6 1617-53-4,
 Amentoflavone 1910-68-5, Methisazone 2013-58-3, Meclocycline
 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2058-46-0,
 Oxytetracycline hydrochloride 2068-78-2, Vincristine sulfate
 2398-96-1, Tolnaftate 2447-57-6, Sulfadoxine 2750-76-7, Rifamide
 2751-09-9, Troleandomycin 3056-17-5, Stavudine 3116-76-5,
 Dicloxacillin 3270-71-1, Nifuraldezone 3374-05-8, Nalidixate sodium
 3424-98-4 3485-14-1, Cyclacillin 3511-16-8, Hetacillin 3521-62-8,
 Erythromycin estolate 3545-67-3, Chloroquine hydrochloride 3570-75-0,
 Nifurthiazole 3577-01-3, Cephaloglycin 3696-28-4, Dipyrithione
 3736-81-0, Diloxanide furoate 3778-73-2, Ifosfamide 3795-88-8,
 Levofuraltadone 3810-74-0, Streptomycin sulfate 3847-29-8,
 Erythromycin lactobionate 3922-90-5, Oleandomycin 3963-95-9,
 Methacycline hydrochloride 4117-65-1, Aspartocin 4197-24-4,
 Carbol-fuchsin 4291-63-8, Cladribine 4299-60-9, Sulfisoxazole
 diolamine 4342-03-4, Dacarbazine 4375-07-9D, Epipodophyllotoxin,
 antibody conjugates 4428-95-9 4575-42-2, Coumermycin sodium
 4697-36-3, Carbenicillin 4800-94-6, Carbenicillin disodium 4803-44-5,
 Levopropylcillin potassium 4803-45-6, Thiphencillin potassium
 4914-30-1, Dehydroemetine 4936-47-4, Nifuratel 5036-03-3, Nifurdazil
 5055-20-9, Nifurquinazol 5118-17-2, Furazolum chloride 5250-39-5,
 Floxacillin 5321-32-4, Hetacillin potassium 5355-16-8, Diaveridine
 5490-27-7, Dihydrostreptomycin sulfate 5536-17-4, Vidarabine
 5560-62-3, Biphenamine hydrochloride 5578-73-4, Sanguinarium chloride
 5579-95-3, Nifurmerone 5585-59-1, Nitrocyline 5588-20-5, Chlordantoin
 5667-71-0, Streptonicozid 5714-05-6, Quindecamine acetate 5714-73-8,
 Methenamine hippurate 5874-95-3, Amicycline 5928-84-7, Penicillin v
 benzathine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(therapeutic methods and compns. relating to isoleucine boroproline
 compds. alone or in combination with other drugs, antibodies, or
 antigens)

IT 1404-90-6, Vancomycin 1404-93-9, Vancomycin
 hydrochloride

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(therapeutic methods and compns. relating to isoleucine boroproline


comps. alone or in combination with other drugs, antibodies, or antigens)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i


PAGE 2-A



RN 1404-93-9 CAPLUS
 CN Vancomycin, hydrochloride (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

— Bu-i

PAGE 2-A



PAGE 2-B

●x HCl

L46 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:656550 CAPLUS Full-text
 DOCUMENT NUMBER: 139:185702
 TITLE: Method for systemic drug delivery through the nail
 INVENTOR(S): Bruno-Raimondi, Alfredo Emilio; Karabelas, Argeris
 Jerry
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068197	A1	20030821	WO 2003-EP1345	20030211 <--
WO 2003068197	A8	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,

LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE,
 SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW
 RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
 SK, TR

AU 2003210243 A1 20030904 AU 2003-210243 20030211 <--
 EP 1492512 A1 20050105 EP 2003-739473 20030211 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005517471 T 20050616 JP 2003-567380 20030211 <--

PRIORITY APPLN. INFO.: GB 2002-3276 A 20020212 <--

WO 2003-EP1345 W 20030211

AB A method for systemically delivering a pharmaceutical composition to a human or animal comprises forming an orifice in a nail of a human or animal by means of a laser-based device and applying a pharmaceutical composition in the orifice, wherein the method provides a controlled release of the pharmaceutical composition. The pharmaceutical composition may be in the form of a liquid, semisolid, solid, solution, gel, emulsion, or powder.

IC ICM A61K009-70

ICS A61B018-20

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 62

IT Encephalitis

Human immunodeficiency virus 1

(Japanese, vaccines against; method for systemic drug delivery through nails)

IT 50-02-2, Dexamethasone 50-06-6, Phenobarbital, biological studies
 50-14-6, Ergocalciferol 50-23-7, Hydrocortisone 50-24-8, Prednisolone
 50-28-2, Estradiol, biological studies 50-48-6, Amitriptyline 50-49-7,
 Imipramine 50-55-5, Reserpine 50-78-2, Acetylsalicylic acid 50-81-7,
 Ascorbic acid, biological studies 51-21-8, Fluorouracil 51-34-3,
 Scopolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological
 studies 51-61-6, Dopamine, biological studies 52-01-7, Spironolactone
 52-53-9, Verapamil 52-86-8, Haloperidol 53-03-2, Prednisone 53-86-1,
 Indomethacin 54-11-5, Nicotine 54-31-9, Furosemide 55-56-1,
 Chlorohexidine 55-63-0, Nitroglycerine 56-40-6, Aminoacetic acid,
 biological studies 56-54-2, Quinidine 56-75-7, Chloramphenicol
 56-85-9, Levoglutamide, biological studies 57-27-2, Morphine, biological
 studies 57-41-0, Phenytoin 57-63-6, Ethinylestradiol 57-83-0,
 Progesterone, biological studies 58-05-9, Folinic acid 58-08-2,
 Caffeine, biological studies 58-22-0, Testosterone 58-32-2,
 Dipyrindamole 58-55-9, Theophylline, biological studies 58-73-1,
 Diphenhydramine 58-85-5, Biotin 58-93-5, Hydrochlorothiazide
 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-42-7,
 Phenylephrine 59-43-8, Thiamine, biological studies 59-67-6, Nicotinic
 acid, biological studies 59-92-7, Levodopa, biological studies
 60-54-8, Tetracycline 61-33-6, Penicillin G, biological studies
 62-49-7, Choline 65-23-6, Pyridoxine 66-22-8, Uracil, biological
 studies 68-19-9, Cyanocobalamin 68-22-4, Norethisterone 68-26-8,
 Retinol 68-89-3, Dipyrone 69-53-4, Ampicillin 69-72-7, Salicylic
 acid, biological studies 72-69-5, Nortriptyline 76-22-2, Camphor
 76-25-5, Triamcinolone acetone 76-57-3, Codeine 77-36-1,
 Chlorthalidone 79-83-4, Pantothenic acid 81-13-0, Dexpanthenol
 83-43-2, Methylprednisolone 83-88-5, Riboflavin, biological studies
 87-08-1, Penicillin V 87-33-2, Isosorbide dinitrate 90-82-4,
 Pseudoephedrine 94-09-7, Benzocaine 94-24-6, Tetracaine 97-59-6,
 Allantoin 98-92-0, Nicotinamide 99-66-1, Valproic acid 103-90-2,
 Acetaminophen 113-15-5, Ergotamine 113-92-8 114-07-8, Erythromycin
 125-28-0, Dihydrocodeine 125-29-1, Hydrocodone 125-71-3,
 Dextromethorphan 126-07-8, Griseofulvin 137-58-6, Lidocaine

146-17-8, Flavin mononucleotide 146-22-5, Nitrazepam 153-18-4,
 Rutoside 298-46-4, Carbamazepine 299-42-3, Ephedrine 302-79-4,
 Tretinoin 303-49-1, Clomipramine 315-30-0, Allopurinol 322-35-0,
 Benserazide 364-62-5, Metoclopramide 378-44-9, Betamethasone
 396-01-0, Triamterene 437-38-7, Fentanyl 439-14-5, Diazepam
 466-99-9, Hydromorphone 469-62-5, Dextropropoxyphene 511-12-6,
 Dihydroergotamine 514-65-8, Biperiden 520-85-4, Medroxyprogesterone
 525-66-6, Propranolol 541-15-1, Levocarnitine 552-79-4,
 N-Methylephedrine 555-30-6, Methyldopa 564-25-0, Doxycycline
 599-79-1, Sulfasalazine 603-00-9, Proxyphylline 616-91-1,
 Acetylcysteine 721-50-6, Prilocaine 723-46-6, Sulfamethoxazole
 738-70-5, Trimethoprim 797-63-7, Levonorgestrel 846-49-1, Lorazepam
 1197-18-8, Tranexamic acid 1400-61-9, Nystatin 1403-66-3, Gentamicin
 1404-04-2, Neomycin 1404-26-8, Polymyxin B 1404-90-6,
 Vancomycin 1406-18-4, Vitamin E 1490-04-6, Menthol 1622-61-3,
 Clonazepam 1812-30-2, Bromazepam 1951-25-3, Amiodarone 2098-66-0,
 Cyproterone 2438-72-4, Bufexamac 2609-46-3, Amiloride 2955-38-6,
 Prazepam 3572-43-8, Bromhexine 3737-09-5, Disopyramide 3930-20-9,
 Sotalol 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4618-18-2,
 Lactulose 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5786-21-0,
 Clozapine 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6809-52-5,
 Teprenone 7085-55-4, Troxerutin 8049-47-6, Pancreatin 9001-62-1,
 Lipase 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies
 9004-61-9, Hyaluronic acid 9005-49-6, Heparin, biological studies
 10118-90-8, Minocycline 10238-21-8, Glibenclamide 10540-29-1,
 Tamoxifen 11032-41-0, Dihydroergotoxin 11041-12-6, Cholestyramine
 11103-57-4, Vitamin A 13292-46-1, Rifampicin 13392-18-2, Fenoterol
 14611-51-9, Selegiline 14838-15-4, Phenylpropanolamine 15307-86-5,
 Diclofenac 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-71-2,
 Cefalexin 15687-27-1, Ibuprofen 16051-77-7, Isosorbide mononitrate
 16110-51-3, Cromoglycic acid 16662-47-8, Gallopamil 17902-23-7,
 Tegafur 18559-94-9, Salbutamol 18683-91-5, Ambroxol 19216-56-9,
 Prazosin 20830-75-5, Digoxin 21829-25-4, Nifedipine 22071-15-4,
 Ketoprofen 22204-53-1, Naproxen 22916-47-8, Miconazole 23031-25-6,
 Terbutaline 23593-75-1, Clotrimazole 24356-60-3, Cefatrexyl
 25614-03-3, Bromocriptine 25655-41-8, Povidoneiodine 25812-30-0,
 Gemfibrozil 25953-19-9, Cefazolin 26787-78-0, Amoxicillin
 26839-75-8, Timolol 27848-84-6, Nicergoline 28860-95-9, Carbidopa
 28981-97-7, Alprazolam 29094-61-9, Glipizide 29122-68-7, Atenolol
 30516-87-1, Zidovudine 31329-57-4, Naftidrofuryl 33419-42-0, Etoposide
 34580-13-7, Ketotifen 36322-90-4, Piroxicam 36505-84-7, Buspirone
 36894-69-6, Labetalol 37517-28-5, Amikacin 37517-30-9, Acebutolol
 38304-91-5, Minoxidil 38396-39-3, Bupivacaine 39562-70-4, Nitrendipine
 41294-56-8, Alfalcaldol 41575-94-4, Carboplatin 41859-67-0,
 Bezafibrate 42399-41-7, Diltiazem 47931-85-1, Salcatonin 49562-28-9,
 Fenofibrate 50679-08-8, Terfenadine 51333-22-3, Budesonide
 51384-51-1, Metoprolol 51481-61-9, Cimetidine 52468-60-7, Flunarizine
 53179-11-6, Loperamide 53994-73-3, Cefaclor 54024-22-5, Desogestrel
 54063-53-5, Propafenone 54182-58-0, Sucralfate 54910-89-3, Fluoxetine
 55142-85-3, Ticlopidine 55268-75-2, Cefuroxime 55837-25-7, Buflomedil
 55985-32-5, Nicardipine 56030-54-7 57808-66-9, Domperidone
 58001-44-8, Clavulanic acid 59122-46-2, Misoprostol 59277-89-3,
 Acyclovir 59467-70-8, Midazolam 60166-93-0, Iopamidol 62571-86-2,
 Captopril 63527-52-6, Cefotaxime 63590-64-7, Terazosin 64221-86-9,
 Imipenem 65277-42-1, Ketoconazole 66085-59-4, Nimodipine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method for systemic drug delivery through nails)


IT

1404-90-6, Vancomycin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method for systemic drug delivery through nails)

RN 1404-90-6 CAPLUS
 CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

— Bu-i

PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:261602 CAPLUS Full-text
DOCUMENT NUMBER: 138:265609
TITLE: Use of neuraminidase inhibitors to prevent
flu-associated bacterial infections
INVENTOR(S): McCullers, Jonathan A.
PATENT ASSIGNEE(S): St. Jude Children's Research Hospital, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026567	A2	20030403	WO 2002-US29417	20020917 <--
WO 2003026567	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002325026	A1	20030407	AU 2002-325026	20020917 <--
US 2004248825	A1	20041209	US 2004-809127	20040325 <--
PRIORITY APPLN. INFO.:			US 2001-325615P	P 20010927 <--
			WO 2002-US29417	W 20020917 <--

AB The invention provides a novel use for neuraminidase inhibitors in chemoprophylactic and treatment methods for the prevention, attenuation, and treatment of bacterial infections that may occur in association with, or as a sequelae of, viral influenza. The prophylactic methods of the invention are particularly suitable for the prevention of secondary bacterial infections, such as, but not limited to, infections of the lower respiratory tract (e.g., pneumonia), middle ear infections (e.g., otitis media), and bacterial sinusitis. The treatment methods are suitable for use in protocols designed to attenuate or treat bacterial infections that occur concurrent with, or as a sequelae of, the flu.

IC ICM A61K

CC 1-5 (Pharmacology)

IT Drugs

Human immunodeficiency virus

(immunosuppression from; neuraminidase inhibitors to prevent flu-associated bacterial infections)

IT 66-79-5, Oxacillin 69-53-4, Ampicillin 147-52-4, Nafcillin 1404-90-6, Vancomycin 3116-76-5, Dicloxacillin 8064-90-2, 18323-44-9, Clindamycin 26787-78-0, Amoxicillin 34787-01-4, Ticarcillin 38821-53-3, Cephadrine 50370-12-2, Cefadroxil 55268-75-2, Cefuroxime 63527-52-6, Cefotaxime 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 74469-00-4, Augmentin 76470-66-1, Loracarbef 76497-13-7, Unasyn 79198-29-1, Amoxicillin-clavulanic acid mixture 79350-37-1, Cefixime 80210-62-4, Cefpodoxime 83905-01-5, Azithromycin

85721-33-1, Ciprofloxacin 86482-18-0, Timentin 88040-23-7, Cefepime
 91832-40-5, Cefdinir 94935-63-4, Ampicillin-sulbactam mixture
 96036-03-2, Meropenem 100986-85-4, Levofloxacin 126602-89-9, Synercid
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(neuraminidase inhibitors to prevent flu-associated bacterial infections,
 and use with antibiotics)

IT 1404-90-6, Vancomycin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)


(neuraminidase inhibitors to prevent flu-associated bacterial infections,
 and use with antibiotics)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



L46 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:77550 CAPLUS Full-text
 DOCUMENT NUMBER: 138:131149
 TITLE: Treatment of neurological disease
 INVENTOR(S): Hesson, David P.; Pelura, Timothy J.; Frazer, Glen D.
 PATENT ASSIGNEE(S): Integra Lifesciences Corp., USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003022879	A1	20030130	US 2002-90442	20020304 <--
US 6689756	B2	20040210		

PRIORITY APPLN. INFO.: US 2001-331359P P 20010302 <--

AB The invention discloses a method of treating an animal infection or neoplasm of cerebrospinal tissue characterized by a risk of death. The method comprises of : (a) injecting a physiolog. acceptable fluid for cerebrospinal perfusion into a first catheter into the cerebrospinal pathway, which fluid for cerebrospinal perfusion has an therapeutically effective amount an agent, the agent selected for effectiveness against the infection as identified or diagnosed; (b) withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and (c) maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume.

IC ICM A61K031-551

ICS A61K031-522; A61K031-43

INCL 514192000; 514220000; 514263360; 514263380

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

IT Brain, disease

Human herpesvirus 3

Human immunodeficiency virus


Human immunodeficiency virus 1

(infection; treatment of neurol. disease)

IT 52-24-4, Thiotepa 54-42-2, Idoxuridine 54-85-3, Isoniazid 56-75-7,
 Chloramphenicol 58-14-0, Pyrimethamine 59-05-2, Methotrexate
 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G,
 biological studies 66-79-5, Oxacillin 68-35-9, Sulfadiazin 68-41-7,
 Cycloserine 69-53-4, Ampicillin 74-55-5, Ethambutol 98-96-4,
 Pyrazinamide 114-07-8, Erythromycin 147-52-4, Nafcillin 147-94-4,
 DepoCyt 148-79-8, Thiabendazole 443-48-1, Metronidazole 536-33-4
 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-90-6,
 Vancomycin 1406-05-9, Penicillin 3116-76-5, Dicloxacillin 6998-60-3,
 Rifamycin 13292-46-1, Rifampin 26787-78-0, Amoxicillin 32986-56-4,
 Tobramycin 55268-74-1, Praziquantel 55268-75-2, Cefuroxime
 58001-44-8 59277-89-3, Acyclovir 61477-96-1, Piperacillin
 62893-19-0, Cefoperazone 68373-14-8, Sulbactam 72558-82-8, Ceftazidime
 73384-59-5, Ceftriaxone 80738-43-8, Lincosamide 88859-04-5,
 Mafosfamide 89786-04-9, Tazobactam 123948-87-8, Topotecan
 154598-52-4, Sustiva
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (treatment of neurol. disease)
 IT 1404-90-6, Vancomycin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (treatment of neurol. disease)
 RN 1404-90-6 CAPLUS
 CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:960674 CAPLUS Full-text

DOCUMENT NUMBER: 138:34097

TITLE: Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide crosslinking agents

INVENTOR(S): Wood, Michael L.; Albagli, David; Van Atta, Reuel B.;
Thien, Douglas Y.; Cheng, Peter C.; Huan, Bingfang

PATENT ASSIGNEE(S) : Naxcor, USA

SOURCE: U.S., 24 pp., Cont.-in-part of U.S. 6,277,570.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 6495676	B1	20021217	US 1999-390124	19990903 <--
US 5616464	A	19970401	US 1994-364339	19941227 <--
US 6005093	A	19991221	US 1995-401630	19950309 <--
US 5767259	A	19980616	US 1995-487034	19950607 <--
US 6004513	A	19991221	US 1995-577121	19951222 <--
US 6277570	B1	20010821	US 1998-149161	19980904 <--
US 2003124547	A1	20030703	US 2002-93626	20020308 <--
US 2003134274	A1	20030717	US 2002-272466	20021015 <--
US 6737239	B2	20040518		

PRIORITY APPLN. INFO.:

US 1993-46568	B2 19930413	<--
US 1994-364339	A2 19941227	<--
US 1995-401630	A2 19950309	<--
US 1995-487034	A2 19950607	<--
US 1995-577121	A2 19951222	<--
US 1998-149161	A2 19980904	<--
US 1999-390124	A2 19990903	<--

AB Methods and compns. are provided for detecting nucleic acid sequences. Probes comprising a crosslinking agent are combined with a sample which may comprise a target sequence which is complementary to the probe. Hybridization is allowed to occur between complementary sequences. The crosslinking agent is activated. Covalent bonds are formed between the probe and the target sequence if they are hybridized to one another. The crosslinked nucleic acids can then be detected to indicate the presence of the target sequence. Also provided are kits comprising reagents. The crosslinking moiety comprises a coumarin derivative linked to a (poly)hydroxy hydrocarbon backbone moiety other than ribose or deoxyribose, and is exemplified by the synthesis of 3-(7-coumarinylmethyl)glycerol and its incorporation at the 5'-terminus of probes.

IC ICM C07H021-00

INCL 536025300; 536025310; 536025370; 435006000

CC 3-1 (Biochemical Genetics)

IT *Borrelia burgdorferi*
Chlamydia
Cytomegalovirus
Dengue virus
Eastern equine encephalitis virus
Ebola virus
Haemophilus ducreyi
Helicobacter pylori
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Hepatitis delta virus
Human T-lymphotropic virus 2
Human herpesvirus 4
 Human immunodeficiency virus 1
 Human immunodeficiency virus 2
Human papillomavirus
Lassa virus
Legionella
Listeria monocytogenes
Microorganism
Mycobacterium
Mycoplasma
Neisseria
Pneumocystis carinii
Respiratory syncytial virus
Salmonella
Treponema pallidum
Western equine encephalitis virus
 (detection of target DNA in; nucleic acid sequence detection employing
 probes comprising non-nucleosidic coumarin derivs. as polynucleotide
 crosslinking agents)

IT 114-07-8; Erythromycin 1404-90-6, Vancomycin 13292-46-1,
 Rifampin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (detection of genes for resistance to; nucleic acid sequence detection
 employing probes comprising non-nucleosidic coumarin derivs. as
 polynucleotide crosslinking agents)


IT 1404-90-6, Vancomycin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (detection of genes for resistance to; nucleic acid sequence detection
 employing probes comprising non-nucleosidic coumarin derivs. as
 polynucleotide crosslinking agents)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

— Bu-i

PAGE 2-A



REFERENCE COUNT:

80

THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:928122 CAPLUS Full-text

DOCUMENT NUMBER: 138:12504

TITLE: Method for assaying biomolecules and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques

INVENTOR(S): Smith, Jack V.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 46 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002182600	A1	20021205	US 2001-829563	20010411 <--
PRIORITY APPLN. INFO.:			US 2001-829563	20010411 <--

AB The present invention is a method for the use of particles made up of nucleotides or fragments of base groups of DNA and RNA mols. herein referred to as synthetic nucleounits which can be used as recognition mols. with specificity and sensitivity significantly greater than that of antibodies which are used in clin. diagnostics, biotechnol., and research. The method for detecting an analyte using nucleounits targeted to the analyte comprises (1) identifying a nucleounit from a mixture of synthetic random sequences of nucleounit libraries, (2) conjugating the nucleounit to an indicator for the analyte, and (3) detecting the analyte using the nucleounit-indicator conjugate in a buffer. Step 1 is carried out by (a) contacting the analyte with the mixture of synthetic random sequences of nucleounit libraries such that some nucleounits bind the analyte, (b) removing the unbound nucleounits by partitioning, and (c) amplifying the remaining nucleounits by PCR to obtain an enriched solution of nucleounits with high affinity for the analyte. Thus, a method and lateral flow test strip for detection of cytomegalovirus (CMV) presence in a biol. sample such as serum or urine is described. The strip is prepared with three solns., one containing anti-CMV antibodies, one containing "nucleounit to CMV antibody conjugated to red microparticles" and "red microparticles", and another containing "nucleounit to colored particles". The "nucleounit" may be an oligonucleotide aptamer specific for anti-CMV antibodies.

IC ICM C12Q001-68

INCL 435006000

CC 9-16 (Biochemical Methods)

IT Angiogenesis

Blood

Blood analysis

Human herpesvirus 3

Human immunodeficiency virus

Leukocyte

Urine analysis

(method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT 50-00-0, Formaldehyde, analysis 50-02-2, Dexamethasone 50-06-6, Phenobarbital, analysis 50-22-6, Corticosterone 50-23-7, Cortisol 50-27-1, Estrinol 50-28-2, Estradiol, analysis 50-33-9, Phenylbutazone, analysis 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, analysis

50-56-6, Oxytocin, analysis 50-67-9, Serotonin, analysis 50-81-7,
 Ascorbic acid, analysis 50-99-7, Glucose, analysis 51-06-9,
 Procainamide 51-35-4, Hydroxyproline 51-48-9, Thyroxine, analysis
 52-39-1, Aldosterone 52-90-4, Cysteine, analysis 53-02-1,
 Tetrahydrocortisol 53-16-7, Estrone, analysis 53-43-0,
 Dehydroepiandrosterone 54-16-0, 5-Hydroxyindoleacetic acid, analysis
 54-36-4, Metyrapone 54-85-3, Isoniazid 55-10-7, Vanillylmandelic acid
 56-40-6, Glycine, analysis 56-41-7, Alanine, analysis 56-54-2,
 Quinidine 56-73-5, Glucose-6-phosphate 56-75-7, Chloramphenicol
 56-81-5, Glycerol, analysis 56-85-9, Glutamine, analysis 56-89-3,
 Cystine, analysis 57-00-1, Creatine 57-12-5, Cyanide, analysis
 57-13-6, Urea, analysis 57-27-2, Morphine, analysis 57-41-0,
 Diphenylhydantoin 57-42-1, Meperidine 57-43-2, Amobarbital 57-48-7,
 Fructose, analysis 57-50-1, Sucrose, analysis 57-53-4, Meprobamate
 57-83-0, Progesterone, analysis 57-88-5, Cholesterol, analysis
 58-08-2, Caffeine, analysis 58-22-0, Testosterone 58-25-3,
 Chlordiazepoxide 58-55-9, Theophylline, analysis 58-86-6, Xylose,
 analysis 59-05-2, Methotrexate 59-23-4, Galactose, analysis 59-30-3,
 analysis 59-67-6, Niacin, analysis 60-18-4, Tyrosine, analysis
 60-27-5, Creatinine 60-92-4, Cyclic AMP 61-90-5, Leucine, analysis
 62-44-2, Phenacetin 63-05-8, Androstenedione 63-42-3, Lactose
 63-68-3, Methionine, analysis 63-91-2, Phenylalanine, analysis
 64-17-5, Ethanol, analysis 64-77-7, Tolbutamide 64-85-7,
 11-Deoxycorticosterone 67-56-1, Methanol, analysis 68-60-0,
 Tetrahydrodeoxycortisol 68-96-2, 17-Hydroxyprogesterone 69-72-7D,
 Salicylic acid, derivs. 69-93-2, Uric acid, analysis 70-18-8,
 Glutathione, analysis 72-18-4, Valine, analysis 72-44-6, Methaqualone
 72-69-5, Nortriptyline 73-32-5, Isoleucine, analysis 76-42-6,
 Oxycodone 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4,
 Pentobarbital 76-75-5, Thiopental 76-99-3, Methadone 77-10-1,
 Phencyclidine 77-21-4, Glutethimide 77-41-8, Methsuximide 77-67-8,
 Ethosuximide 79-14-1, Glycolic acid, analysis 79-83-4, Pantothenic
 acid 80-92-2 81-25-4, Cholic acid 82-58-6, Lysergic acid 83-44-3,
 Deoxycholic acid 83-88-5, Riboflavin, analysis 86-34-0, Phensuximide
 87-86-5, Pentachlorophenol 97-31-4, Normetanephine 99-66-1, Valproic
 acid 103-90-2, Acetaminophen 107-21-1, Ethylene glycol, analysis
 113-18-8, Ethchlorvynol 123-63-7, Paraldehyde 125-33-7, Primidone
 125-64-4, Methyprylon 127-17-3, Pyruvic acid, analysis 137-58-6,
 Lidocaine 143-74-8, Phenolsulfonphthalein 145-13-1, Pregnenolone
 152-58-9, 11-Deoxycortisol 298-46-4, Carbamazepine 299-42-3, Ephedrine
 300-62-9, Amphetamine 302-04-5, Thiocyanate, analysis 302-17-0,
 Chloral hydrate 306-08-1, Homovanillic acid 359-83-1, Pentazocine
 438-60-8, Protriptyline 439-14-5, Diazepam 451-13-8, Homogentisic acid
 466-99-9, Hydromorphone 469-62-5, Propoxyphene 487-90-1,
 Porphobilinogen 521-18-6, Dihydrotestosterone 525-66-6, Propranolol
 537-46-2, Methamphetamine 553-12-8, Protoporphyrin 555-30-6,
 Methyl dopa 591-81-1, γ -Hydroxybutyric acid 604-75-1, Oxazepam
 635-65-4, Bilirubin, analysis 651-48-9, Dehydroepiandrosterone sulfate
 846-49-1, Lorazepam 1098-45-9, Pregnanetriol 1319-82-0, Aminocaproic
 acid 1330-20-7, Xylene, analysis 1393-25-5, Secretin 1403-66-3,
 Gentamicin 1404-90-6, Vancomycin 1622-61-3, Clonazepam
 1668-19-5, Doxepin 3737-09-5, Disopyramide 4205-90-7, Clonidine
 4429-04-3, Fructosamine 4685-14-7, Paraquat 4697-36-3, Carbenicillin
 5001-33-2, Metanephine 5817-39-0, Reverse triiodothyronine 6027-13-0,
 Homocysteine 6893-02-3, Triiodothyronine 7439-89-6, Iron, analysis
 7439-92-1, Lead, analysis 7439-93-2, Lithium, analysis 7439-95-4,
 Magnesium, analysis 7439-97-6, Mercury, analysis 7439-98-7,
 Molybdenum, analysis 7440-02-0, Nickel, analysis 7440-28-0, Thallium,
 analysis 7440-47-3, Chromium, analysis 7440-57-5, Gold, analysis
 7440-66-6, Zinc, analysis 7440-70-2, Calcium, analysis 7782-49-2,

Selenium, analysis 7783-06-4, Hydrogen sulfide, analysis 8063-07-8, Kanamycin 9000-86-6, Alanine aminotransferase 9000-92-4, Amylase 9000-94-6, Antithrombin 9001-08-5, Pseudocholinesterase 9001-10-9, Pepsinogen 9001-15-4, Creatine kinase 9001-58-5, Isocitrate dehydrogenase 9001-62-1, Lipase 9001-63-2, Lysozyme 9001-77-8, Acid phosphatase 9001-80-3, Phosphofructokinase 9001-91-6, Plasminogen 9002-60-2, Adrenocorticotrophic hormone, analysis 9002-61-3, Chorionic gonadotropin 9002-64-6, Parathyroid hormone 9002-68-0, Follicle stimulating hormone 9002-71-5, Thyroid stimulating hormone 9002-72-6, Growth hormone 9002-76-0, Gastrin 9004-07-3, Chymotrypsin 9004-10-8, Insulin, analysis 9007-12-9, Calcitonin 9007-92-5, Glucagon, analysis 9014-48-6, Transketolase 9015-94-5, Renin, analysis 9024-52-6, Aldolase 9035-54-5, Placental lactogen 9035-68-1, Proinsulin 9035-81-8, Antitrypsin 11000-17-2, Antidiuretic hormone 11016-39-0, Properdin 12794-10-4D, Benzodiazepine, derivs. 14797-65-0, Nitrite, analysis 14838-15-4, Phenylpropanolamine 15687-27-1, Ibuprofen 17617-23-1, Flurazepam 20830-75-5, Digoxin 23887-31-2, Clorazepate 24305-27-9, Thyrotropin-releasing hormone 24959-67-9, Bromide, analysis 26316-36-9, Uroporphyrin 27121-71-7, Coproporphyrin 29679-58-1, Fenoprofen 32795-44-1, n-Acetylprocainamide 32986-56-4, Tobramycin 37221-79-7, Vasoactive intestinal polypeptide 37517-28-5, Amikacin 39335-01-8, Macroamylase 51481-61-9, Cimetidine 54143-55-4, Flecainide 56391-56-1, Netilmicin 59112-80-0, c-Peptide 59763-91-6, Pancreatic polypeptide 59865-13-3, Cyclosporine 67763-96-6, Somatomedin c 69776-17-6, 85876-02-4, Glutamyltransferase 152923-57-4, Lutropin

RL: ANT (Analyte); ANST (Analytical study)

(method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

IT 1404-90-6, Vancomycin

RL: ANT (Analyte); ANST (Analytical study)


(method for assaying biomols. and other constituents using indicator conjugates with synthetic nucleounits in lateral flow, liquid, and dry chemical techniques)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

— Bu-i

PAGE 2-A



L46 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:717056 CAPLUS Full-text

DOCUMENT NUMBER: 137:226655

DOCUMENT NUMBER: 1974220000
TITLE: Methods for treatment of neuro- and nephro- disorders

and therapeutic toxicities using aminothiols compounds

INVENTOR(S): Stogniew, Martin; Alberts, David S.; Kaplan, Edward H.

PATENT ASSIGNEE(S): U.S. Bioscience, Inc., USA; Medimmune Oncology Inc.

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Division of Ser. No. US

1999-429290, filed on 28 Oct 1999

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2002132795	A1	20020919	US 2002-137686	20020503 <--
US 7105575	B2	20060912		
US 5994409	A	19991130	US 1997-987550	19971209 <--
EP 1537861	A2	20050608	EP 2005-3650	19981209 <--
EP 1537861	A3	20050615		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY

US 6586476	B1	20030701	US 1999-429290	19991028 <--
US 2006040903	A1	20060223	US 2005-258335	20051025 <--
JP 2006188532	A	20060720	JP 2006-64774	20060309 <--
US 2006270636	A1	20061130	US 2006-501949	20060809 <--
PRIORITY APPLN. INFO.:			US 1997-987550	A3 19971209 <--
			US 1999-429290	A3 19991028 <--
			EP 1998-962011	A3 19981209 <--
			JP 2000-523983	A3 19981209 <--
			US 2002-137686	A1 20020503 <--

OTHER SOURCE(S): MARPAT 137:226655

AB The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate (amifostine) and other aminothiol compds. to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents. Cancer patients with neurotoxicities from chemotherapy treatment were treated with amifostine.

IC ICM A61K031-66
ICS A61K031-135; A61K031-16; A61K031-13
INCL 514114000; X51-466.5; X51-464.6; X51-462.5

CC 1-12 (Pharmacology)
Section cross-reference(s): 4

IT Anti-AIDS agents
Antibiotics
Antihypertensives
Antitumor agents
Antiviral agents
Chemotherapy
Diabetes mellitus
Drugs
Fungicides
Radiotherapy
(toxicity from; treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compds.)

IT AIDS (disease)
Hypertension
Neoplasm
(toxicity in treatment of; treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compds.)


IT 57-22-7, Vincristine 865-21-4, Vinblastine 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-90-6, Vancomycin 3056-17-5, Stavudine 7481-89-2, Zalcitabine 8063-07-8, Kanamycin 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 30516-87-1, 3'-Azido-3'-deoxythymidine 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 37517-28-5, Amikacin 41575-94-4, Carboplatin 69655-05-6, Didanosine 95058-81-4, Gemcitabine 114977-28-5, Docetaxel 125317-39-7, Navelbine 134678-17-4, Lamivudine
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(toxicity from; treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compds.)

IT 1404-90-6, Vancomycin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(toxicity from; treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compds.)

RN 1404-90-6 CAPLUS
CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT:

74

THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:695717 CAPLUS Full-text

DOCUMENT NUMBER: 137:210971

TITLE: Treatment of neurological disease with therapeutic agent-containing cerebrospinal perfusion fluid

INVENTOR(S): Hesson, David P.; Pelura, Timothy J.; Frazer, Glenn D.

PATENT ASSIGNEE(S): Neuron Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069893	A2	20020912	WO 2002-US6108	20020228 <--
WO 2002069893	A3	20050519		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002242293	A1	20020919	AU 2002-242293	20020228 <--
PRIORITY APPLN. INFO.:			US 2001-798774	A 20010302 <--
			WO 2002-US6108	W 20020228 <--

AB Provided is, among other things, a method of treating in an animal infection or neoplasm of cerebrospinal tissue characterized by a risk of death, the method comprising: (a) injecting a physiologically acceptable fluid for cerebrospinal perfusion into a first catheter into the cerebrospinal pathway, which fluid for cerebrospinal perfusion has a therapeutically effective amount of an agent, the agent selected for effectiveness against the infection as identified or diagnosed; (b) withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and (c) maintaining the flow for a period of time adapted to perfuse at least 1 CSF volume

IC ICM A61K

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

IT Human immunodeficiency virus

Nervous system, disease

(infection; treatment of neurological disease with therapeutic agent-containing cerebrospinal perfusion fluid)

IT Alkylating agents, biological

Animals

Anthelmintics

Anti-AIDS agents

Anti-infective agents

Antibacterial agents

Antimicrobial agents

Antitumor agents

Antiviral agents

Endotoxemia

Eubacteria

Flow

Fungi

Fungicides
 Leukemia
 Mycoplasma pneumoniae
 Nervous system, disease
 Nervous system, neoplasm
 Neuroglia, neoplasm
 Protozoacides
 Tuberculostatics
 Virus

(treatment of neurol. disease with therapeutic agent-containing cerebrospinal perfusion fluid)

IT 52-24-4, Thiotepe 54-42-2, Idoxuridine 54-85-3, Isoniazid 56-75-7;
 Chloramphenicol 58-14-0, Pyrimethamine 59-05-2, Methotrexate
 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G,
 biological studies 66-79-5, Oxacillin 68-35-9, Sulfadiazine 68-41-7,
 Cycloserine 69-53-4, Ampicillin 74-55-5, Ethambutol 98-96-4,
 Pyrazinamide 114-07-8, Erythromycin 147-52-4, Nafcillin 147-94-4,
 Cytarabine 443-48-1, Metronidazole 536-33-4, Ethioniamide 1397-89-3,
 Amphotericin B 1403-66-3, Gentamicin 1404-90-6, Vancomycin
 1406-05-9D, Penicillin, compds. 3116-76-5, Dicloxacillin 6998-60-3,
 Rifamycin 13292-46-1, Rifampin 26787-78-0, Amoxicillin 32986-56-4,
 Tobramycin 55268-74-1, Praziquantel 55268-75-2, Cefuroxime
 59277-89-3, Acyclovir 61477-96-1, Piperacillin 62893-19-0,
 Cefoperazone 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone
 79198-29-1 88859-04-5, Mafosfamide 94935-63-4, Ampicillin/sulbactam
 123683-33-0 123948-87-8, Topotecan 154598-52-4, Efavirenz
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(treatment of neurol. disease with therapeutic agent-containing cerebrospinal perfusion fluid)


IT 1404-90-6, Vancomycin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(treatment of neurol. disease with therapeutic agent-containing cerebrospinal perfusion fluid)

RN 1404-90-6 CAPLUS
 CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



L46 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:71906 CAPLUS Full-text
 DOCUMENT NUMBER: 136:123678
 TITLE: Enhancement of the action of anti-infective agents
 using an administration medium containing nitrous
 oxide
 INVENTOR(S): Meyer, Petrus Johannes
 PATENT ASSIGNEE(S): Pitmy International N.V., Neth. Antilles
 SOURCE: PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005850	A2	20020124	WO 2001-ZA98	20010719 <--
WO 2002005850	A3	20030109		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2416512 A1 20020124 CA 2001-2416512 20010719 <--
 ZA 2003000366 A 20040629 ZA 2003-366 20030114 <--

PRIORITY APPLN. INFO.: ZA 2000-3644 A 20000719 <--
 WO 2001-ZA98 W 20010719 <--

AB The invention provides a method of enhancing the action of anti-infective agents, i.e., antimicrobial agents, anthelmintics, and anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, characterized in that the agent is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas. The administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, α -linolenic acid, γ -linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5 ω 3], docosahexaenoic acid [C22: 6 ω 3], ricinoleic acid and derivs. thereof selected from the group consisting of the C1-6 alkyl esters, the glycerol-polyethylene glycol esters and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid-based oils, such as castor oil with ethylene oxide. For example, an aqueous emulsion was prepared by mixing 30 g vitamin F Et ester with 10 g Cremophor RH40, 2.2 g Me paraben, 0.08 g Bu hydroxyanisole, and 0.23 g Bu hydroxytoluene. Into 942.5 g of the stock nitrous oxide aqueous solution, 2.5 g sodium Pr paraben and 2.5 g Germall 115 were added with stirring at room temperature. The oily composition was then emulsified into the aqueous solution to obtain a nanolipid vesicle formulation. A non-aqueous solution of nitrous oxide in carrier formulation was also prepared. Polyoxyl hydrogenated castor oil (1.15 kg) was mixed with 2.35 kg vitamin F Et ester, 150.0 g α -tocopherol, and 1.295 kg PEG 400 at 40°. The oily mixture was gassed with nitrous oxide for 3 h at 2 bar and then heated at 70°. To the heated gas-oil mixture, 50.0 g Me paraben and 5.0 g butylated hydroxytoluene were added and the mixture was allowed to cool down. When the mixture was cooled down to approx. 40°, 5.00 kg pyrazinamide (particle size <40 μ m) was added while continuously mixing and the mixture was addnl. gassed with nitrous oxide at 20 kPa for 30 min. After the mixture was cooled down to reach room temperature, it was encapsulated in soft gel capsules. Encapsulation of pyrazinamide in lipid vesicles led to a 65-70% decrease in BCG (bacillus Calmette-Guerin) viability within a 2-h incubation with no moving BCG observed, while the incubation with free pyrazinamide resulted in the appearance of single live bacteria with a few granuloma-type clumps, which gradually secreted single live bacteria.

IC ICM A61K047-00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 10, 15

IT Anthelmintics

Anti-AIDS agents

Anti-infective agents

Antibacterial agents

Antibacterial agents

Antibiotics

Antimalarials

Antimicrobial agents

Antiviral agents

Drug bioavailability

Encapsulation

Fungicides

Parasiticides

Tuberculostatics

(lipid vehicles containing nitrous oxide for enhancement of activity of anti-infective agents)

IT 50-59-9, Cephaloridine 54-42-2, Idoxuridine 54-85-3 56-75-7, Chloramphenicol 57-62-5, Chlortetracycline 57-67-0, Sulfaguanidine 57-68-1, Sulfadimidine 57-92-1, Streptomycin, biological studies 60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G, biological studies 61-72-3, Cloxacillin 64-75-5, Tetracycline Hydrochloride 65-85-0, Benzoic Acid, biological studies 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 68-35-9, Sulfadiazine 68-41-7, Cycloserine 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 70-00-8, Trifluridine 74-55-5, Ethambutol 79-09-4, Propionic Acid, biological studies 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-35-3, Sulfamethoxypyridazine 85-73-4, Phthalylsulfathiazole 87-08-1, Penicillin V 98-96-4, Pyrazinamide 98-97-5, Pyrazinoic acid 100-97-0, Methenamin, biological studies 112-38-9, Undecylenic Acid 114-07-8, Erythromycin 116-43-8, Succinylsulfathiazole 122-11-2, Sulfadimethoxine 124-07-2, Caprylic Acid, biological studies 126-07-8, Griseofulvin 127-33-3, Demeclocycline 127-56-0, Sulfacetamide sodium 127-69-5, Sulfafurazole 144-80-9, Sulfacetamide 144-83-2, Sulfapyridine 147-52-4, Nafcillin 152-47-6, Sulfametopyrazine 288-32-4D, Imidazole, derivs. 389-08-2, Nalidixic Acid 536-33-4, Ethionamide 564-25-0, Doxycycline 599-79-1, Sulfasalazine 651-06-9, Sulfamethoxydiazine 723-46-6, Sulfamethoxazole 768-94-5, Amantadine 777-11-7, Haloprogyn 914-00-1, Methacycline 1066-17-7, Colistin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-26-8, Polymyxin B 1404-90-6, Vancomycin 1405-20-5, Polymyxin B Sulfate 1405-41-0, Gentamicin Sulfate 1405-87-4, Bacitracin 1405-89-6, Bacitracin Zinc 1695-77-8, Spectinomycin 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2398-96-1, Tolnaftate 2447-57-6, Sulfadoxine 3056-17-5, Stavudine 3116-76-5, Dicloxacillin 3511-16-8, Hetacillin 4299-60-9, Sulfisoxazole diolamine 4428-95-9, Foscarnet 4697-36-3, Carbenicillin 5250-39-5, Flucloxacillin 5536-17-4, Vidarabine 6489-97-0, Metampicillin 7481-89-2, Zalcitabine 7681-11-0, Potassium Iodide, biological studies 7681-93-8, Natamycin 8063-07-8, Kanamycin 8064-90-2, Co-Trimoxazole 10118-90-8, Minocycline 11003-38-6, Capreomycin 13009-99-9, Mafenide Acetate 13292-46-1, Rifampicin 13392-28-4, Rimantadine 13721-01-2D, derivs. 13838-08-9, Azidamphenicol 14698-29-4, Oxolinic Acid 15318-45-3, Thiamphenicol 15686-71-2, Cefalexin 18323-44-9, Clindamycin 19562-30-2, Piromidic Acid 20461-54-5, Iodide, biological studies 22199-08-2, Silver sulfadiazine 22832-87-7, Miconazole nitrate 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25953-19-9, Cephalolin 26787-78-0, Amoxicillin 27025-49-6, Carfecillin 27220-47-9, Econazole 27726-31-4, Pivcephalexin 28088-64-4, Aminosalicic acid 28657-80-9, Cinoxacin 29342-05-0, Ciclopirox 30516-87-1, Zidovudine 32886-97-8, Pivmecillinam 32986-56-4, Tobramycin 33817-20-8, Pivampicillin 34444-01-4, Cephamandole 34787-01-4, Ticarcillin 35531-88-5, Carindacillin 35607-66-0, Cefoxitin 36791-04-5, Ribavirin 37091-66-0, Azlocillin 37517-28-5, Amicacin 38821-53-3, Cephadrine 39809-25-1, Penciclovir 40034-42-2, Acrosoxacin 41621-49-2, Ciclopirox olamine 47747-56-8, Talampicillin 49842-07-1, Tobramycin sulfate 50370-12-2, Cefadroxil 50972-17-3, Bacampicillin 51481-65-3, Mezlocillin 51627-14-6, Cefatrizine 51940-44-4, Pipemidic Acid 53994-73-3, Cefaclor 55268-75-2, Cefuroxim 56391-56-1, Netilmicin 58001-44-8, Clavulanic Acid 59277-89-3, Acyclovir 60925-61-3, Ceforanide 61036-62-2, Teicoplanin 61270-58-4, Cefonicid 61318-90-9, Sulconazole 61477-96-1, Piperacillin 61622-34-2, Cefotiam 62587-73-9, Cefsulodin 62893-19-0, Cefoperazone 63469-19-2, Apalcillin

63527-52-6, Cefotaxime 63744-80-9, Cephamycin 64211-45-6, Oxiconazole
 64221-86-9, Imipenem 64544-07-6, Cefuroxime axetil 64872-76-0,
 Butoconazole 64952-97-2, Latamoxef 65085-01-0, Cefmenoxime
 65243-33-6, Cefetamet Pivoxil 65277-42-1, Ketoconazole 65472-88-0,
 Naftifine 65899-73-2, Tioconazole 66148-78-5, Temocillin 67915-31-5,
 Terconazole 68373-14-8, Sulbactam 68401-81-0, Ceftizoxime
 69655-05-6, Didanosine 69712-56-7, Cefotetan 69739-16-8, Cefodizime
 70458-92-3, Pefloxacin 70458-96-7, Norfloxacin 70797-11-4, Cefpiramide
 72558-82-8, Ceftazidime 72559-06-9, Rifabutin 73384-59-5, Ceftriaxone
 74011-58-8, Enoxacin 76168-82-6, Ramoplanin 76470-66-1, Loracarbef
 77181-69-2, Sorivudine 78110-38-0, Aztreonam 79350-37-1, Cefixime
 79660-72-3, Fleroxacin 80214-83-1, Roxithromycin 81103-11-9,
 Clarithromycin 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin
 83905-01-5, Azithromycin 84625-61-6, Itraconazole 85721-33-1,
 Ciprofloxacin 86386-73-4, Fluconazole 86393-37-5, Amifloxacin
 88040-23-7, Cefepime 89786-04-9, Tazobactam 91161-71-6, Terbinafine
 91832-40-5, Cefdinir 92665-29-7, Cefprozil 93106-60-6, Enrofloxacin
 96036-03-2, Meropenem 97519-39-6, Ceftibuten 98079-51-7, Lomefloxacin
 100490-36-6, Tosufloxacin 100986-85-4, Levofloxacin 101363-10-4,
 Rufloxacin 104227-87-4, Famciclovir 110871-86-8, Sparfloxacin
 124832-26-4, Valacyclovir 124858-35-1, Nadifloxacin 126602-89-9, RP
 59500 134678-17-4, Lamivudine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(lipid vehicles containing nitrous oxide for enhancement of activity of
 anti-infective agents)

IT 1404-90-6, Vancomycin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)


(lipid vehicles containing nitrous oxide for enhancement of activity of
 anti-infective agents)

RN 1404-90-6 CAPLUS


CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



—Bu-i



L46 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:10505 CAPLUS Full-text
 DOCUMENT NUMBER: 136:79729
 TITLE: Antimicrobial peptides and methods of use thereof
 INVENTOR(S): Hancock, Robert E. W.; Zhang, Lijuan
 PATENT ASSIGNEE(S): The University of British Columbia, Can.
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000687	A2	20020103	WO 2001-CA918	20010627 <--
WO 2002000687	A3	20020906		
WO 2002000687	A9	20030918		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,

IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GW, ML, MR, NE, SN, TD, TG

US 6337317	B1	20020108	US 2000-604864	20000627 <--
CA 2412531	A1	20020103	CA 2001-2412531	20010627 <--
EP 1294745	A2	20030326	EP 2001-944839	20010627 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507228	T	20040311	JP 2002-505809	20010627 <--
NZ 523183	A	20041224	NZ 2001-523183	20010627 <--
US 2002156017	A1	20021024	US 2002-42872	20020108 <--
US 6747007	B2	20040608		

PRIORITY APPLN. INFO.:

US 2000-604864	A	20000627 <--
WO 2001-CA918	W	20010627 <--

OTHER SOURCE(S): MARPAT 136:79729

AB A class of cationic, polyphemusin-like peptides having antimicrobial activity is provided. Examples of such peptides include FRWCFRVCYKGRCRYKCR (SEQ ID NO:3), RRWCFRVCYKGFCRYKCR (SEQ ID NO:4), and RRWCFRVCYRGRFCYRKCR (SEQ ID NO:11) (I). Also provided are methods for inhibiting the growth of microbes such as bacteria, yeast and viruses utilizing the peptides of the invention. The peptides are particularly useful for inhibiting endotoxemia in a subject. I provided protection against endotoxemia in mice.

IC ICM C07K007-00

CC 1-5 (Pharmacology)

IT Antibacterial agents

Antiviral agents

Candida albicans

Circular dichroism

Enterococcus faecalis

Escherichia coli

Fungicides

Gram-negative bacteria

Gram-positive bacteria

Hepatitis B virus

Hepatitis C virus

Herpesviridae

Human

Human herpesvirus

Human immunodeficiency virus 1

Influenza A virus

Pseudomonas aeruginosa

Salmonella minnesota

Salmonella typhimurium

Staphylococcus aureus

Staphylococcus epidermidis

Vesicular stomatitis virus

(antimicrobial peptides and methods of use thereof)

IT 56-75-7, Chloramphenicol 57-92-1, Streptomycin, biological studies
60-54-8, Tetracycline 61-32-5, Methicillin 61-33-6, Penicillin G,
biological studies 61-72-3, Cloxacillin 66-79-5, Oxacillin 67-20-9,
Nitrofurantoin 69-53-4, Ampicillin 87-08-1, Penicillin V 114-07-8,
Erythromycin 147-52-4, Nafcillin 153-61-7, Cephalothin 389-08-2,
Nalidixic acid 564-25-0, Doxycycline 643-22-1, Erythromycin stearate
723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 1264-62-6,
Erythromycin ethylsuccinate 1403-66-3, Gentamicin 1404-90-6,
Vancomycin 1406-05-9D, Penicillin, compds. 3116-76-5, Dicloxacillin
3521-62-8, Erythromycin estolate 3847-29-8, Erythromycin lactobionate
4697-36-3, Carbenicillin 8063-07-8, Kanamycin 9001-63-2, Lysozyme
10118-90-8, Minocycline 11111-12-9D, Cephalosporin, compds.
12650-69-0, Mupirocin 13292-46-1, Rifampin 18323-44-9, Clindamycin
23067-13-2, Erythromycin gluceptate 25953-19-9, Cefazolin 26787-78-0,

Amoxicillin 28657-80-9, Cinoxacin 32986-56-4, Tobramycin 34444-01-4,
 Cefamandole 34787-01-4, Ticarcillin 35607-66-0, Cefoxitin
 37091-66-0, Azlocillin 37517-28-5, Amikacin 51481-65-3, Mezlocillin
 53994-73-3, Cefaclor 55268-75-2, Cefuroxime 56391-56-1, Netilmicin
 56796-20-4, Cefmetazole 61036-62-2, Teicoplanin 61270-58-4, Cefonicid
 61477-96-1, Piperacillin 62587-73-9, Cefsulodin 62893-19-0,
 Cefoperazone 63527-52-6, Cefotaxime 64221-86-9, Imipenem 65052-63-3,
 Cefetamet 68401-81-0, Ceftizoxime 69712-56-7, Cefotetan 70458-96-7,
 Norfloxacin 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone
 74011-58-8, Enoxacin 76470-66-1, Loracarbef 78110-38-0, Aztreonam
 79350-37-1, Cefixime 79660-72-3, Fleroxacin 80210-62-4, Cefpodoxime
 81103-11-9, Clarithromycin 82419-36-1, Ofloxacin 83200-96-8D,
 Carbapenem, compds. 83905-01-5, Azithromycin 85721-33-1, Ciprofloxacin
 88040-23-7, Cefepime 92665-29-7, Cefprozil 98079-51-7, Lomefloxacin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptide in combination with; antimicrobial peptides and methods of use thereof)

IT 1404-90-6, Vancomycin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(peptide in combination with; antimicrobial peptides and methods of use thereof)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

— Bu-i

PAGE 2-A



L46 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:635933 CAPLUS Full-text

DOCUMENT NUMBER: 135:215973

TITLE: Use of peptide conjugates for enhancing drug delivery
across biological membranes and tissues

INVENTOR(S): Rothbard, Jonathan B.; Wender, Paul A.

PATENT ASSIGNEE(S): Cellgate, Inc., USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062297	A1	20010830	WO 2001-US4459	20010209 <--
WO 2001062297	A9	20030109		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002009491	A1	20020124	US 2001-779693	20010207 <--
CA 2400099	A1	20010830	CA 2001-2400099	20010209 <--
EP 1263469	A1	20021211	EP 2001-909135	20010209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003523982	T	20030812	JP 2001-561360	20010209 <--
MX 2002PA07820	A	20021023	MX 2002-PA7820	20020813 <--
PRIORITY APPLN. INFO.:				
			US 2000-182166P	P 20000214 <--
			US 2001-779693	A 20010207 <--
			WO 2001-US4459	W 20010209 <--

AB This invention provides compns. and methods for enhancing delivery of drugs and other agents across a biol. barrier, including epithelial tissues such as the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compns. and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compns. and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine mols. that are preferably between about 6 and 50 residues in length. Taxol conjugates with a heptamer of arginine was soluble in water in contrast with taxol itself. The conjugate was equally potent when assayed for biol. activity using standard cytotoxicity assay.

IC ICM A61K047-42

ICS A61K047-48

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1

IT AIDS (disease)

Alzheimer's disease

Analgesics

Antibacterial agents

Antiviral agents

Asthma

Biological transport

Blood-brain barrier

Cystic fibrosis

Epilepsy

Epithelium

Fungicides

Helicobacter pylori

Immunosuppressants

Infection

Ischemia

Membrane, biological

Multiple sclerosis

Neoplasm

Pain

Parkinson's disease

Permeation enhancers

Schizophrenia

Skin

(use of peptide conjugates for enhancing drug delivery across biol. membranes and tissues)

IT 50-18-0, Cyclophosphamide 50-36-2, Cocaine 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 51-05-8, Novocaine 51-21-8, 5-Fluorouracil 54-42-2, Idoxuridine 55-86-7, Mechlorethamine hydrochloride 59-05-2, Methotrexate 59-46-1, Procaine 60-54-8, Tetracycline 64-86-8, Colchicine 65-45-2, Salicylamide 66-79-5, Oxacillin 69-53-4, Ampicillin 70-00-8, Trifluridine 80-08-0, Dapsone 94-09-7, Benzocaine 94-24-6, Tetracaine 96-88-8, Mepivacaine 100-33-4, Pentamidine 114-07-8, Erythromycin 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 137-58-6, Lidocaine 147-52-4, Nafcillin 147-94-4, Cytarabine 154-42-7, 6-Thioguanine 154-93-8, Carmustine 446-86-6, Azathioprine 499-67-2, Proparacaine 599-79-1, Sulfasalazine 671-16-9, Procarbazine 721-50-6, Prilocaine 865-21-4, Vinblastine 1400-61-9, Nystatin 1403-66-3, Gentamycin 1404-00-8, Mitomycin 1404-90-6, Vancomycin 1406-05-9, Penicillin 3056-17-5, Stavudine 4342-03-4, Dacarbazine 4428-95-9, Foscarnet 7481-89-2, Zalcitabine 9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin 10118-90-8, Minocycline 11000-17-2, Vasopressin

11056-06-7, Bleomycin 11111-12-9, Cephalosporin 12633-72-6,
 Amphotericin 13292-46-1, Rifampin 13392-28-4, Rimantadine
 15663-27-1, Cisplatin 16110-51-3, Cromolyn 20830-81-3, Daunorubicin
 21679-14-1, Fludarabine 22916-47-8, Miconazole 23214-92-8, Doxorubicin
 23593-75-1, Clotrimazole 26787-78-0, Amoxycillin 27220-47-9, Econazole
 29342-05-0, Ciclopirox 29767-20-2, Teniposide 30516-87-1, Zidovudine
 33419-42-0, Etoposide 36637-18-0, Etidocaine 36791-04-5, Ribavirin
 38396-39-3, Bupivacaine 53910-25-1, Pentostatin 58822-25-6, Leucine
 enkephalin 59277-89-3, Acyclovir 63527-52-6, Cefotaxime 65271-80-9,
 Mitoxantrone 65277-42-1, Ketoconazole 65472-88-0, Naftifine
 69049-73-6, Nedocromil 69655-05-6, Didanosine 73384-59-5, Ceftriaxone
 77181-69-2, Sorivudine 79217-60-0, Cyclosporin 82410-32-0, Ganciclovir
 84057-95-4, Ropivacaine 84625-61-6, Itraconazole 85721-33-1,
 Ciprofloxacin 86386-73-4, Fluconazole 91161-71-6, Terbinafine
 104227-87-4, Famciclovir 104987-11-3, Tacrolimus 113852-37-2,
 Cidofovir 124832-26-4, Valacyclovir 357417-87-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of peptide conjugates for enhancing drug delivery across biol.
 membranes and tissues)

IT 1404-90-6, Vancomycin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of peptide conjugates for enhancing drug delivery across biol.
 membranes and tissues)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:614284 CAPLUS Full-text

DOCUMENT NUMBER: 135:191244

TITLE: Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents

INVENTOR(S): Wood, Michael L.; Albagli, David; Van Atta, Reuel B.; Cheng, Peter C.; Huan, Bingfang; Thien, Douglas Y.

PATENT ASSIGNEE(S): Naxcor, USA

SOURCE: U.S., 24 pp., Cont.-in-part of U.S. 6,005,093.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6277570	B1	20010821	US 1998-149161	19980904 <--
US 5616464	A	19970401	US 1994-364339	19941227 <--
US 6005093	A	19991221	US 1995-401630	19950309 <--
US 5767259	A	19980616	US 1995-487034	19950607 <--
US 6004513	A	19991221	US 1995-577121	19951222 <--
US 6495676	B1	20021217	US 1999-390124	19990903 <--
US 2003124547	A1	20030703	US 2002-93626	20020308 <--
US 2003134274	A1	20030717	US 2002-272466	20021015 <--
US 6737239	B2	20040518		

PRIORITY APPLN. INFO.:

US 1993-46568	B2	19930413 <--
US 1994-364339	A2	19941227 <--
US 1995-401630	A2	19950309 <--
US 1995-487034	A2	19950607 <--
US 1995-577121	A2	19951222 <--
US 1998-149161	A2	19980904 <--

US 1999-390124

A2 19990903 <--

AB Methods and compns. are provided for detecting nucleic acid sequences. Probes comprising a crosslinking agent are combined with a sample which may comprise a target sequence which is complementary to the probe. Hybridization is allowed to occur between complementary sequences. The crosslinking agent is activated. Covalent bonds are formed between the probe and the target sequence if they are hybridized to one another. The crosslinked nucleic acids can then be detected to indicate the presence of the target sequence. Also provided are kits comprising reagents.

IC ICM C12Q001-68
ICS C07H021-00

INCL 435006000

CC 3-1 (Biochemical Genetics)

IT Antibiotic resistance
Blood
Borrelia burgdorferi
Crosslinking agents
Cytomegalovirus
Dengue virus
Eastern equine encephalitis virus
Ebola virus
Enterobacteriaceae
Fluorescent substances
Haemophilus ducreyi
Helicobacter pylori
Human T-lymphotropic virus 2
Human herpesvirus 4
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Human papillomavirus
Labels
Lassa virus
Microorganism
Neisseria gonorrhoeae
Nucleic acid hybridization
Pneumocystis carinii
Radioactive substances
Respiratory syncytial virus
Salmonella
Test kits
Treponema pallidum
Western equine encephalitis virus
(nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide-crosslinking agents)

IT 114-07-8, Erythromycin 1404-90-6, Vancomycin 13292-46-1,
Rifampin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance gene; nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide-crosslinking agents)


IT 1404-90-6, Vancomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance gene; nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivs. as polynucleotide-crosslinking agents)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT:

79

THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:525934 CAPLUS Full-text
 DOCUMENT NUMBER: 135:97511
 TITLE: Reduction in bacterial colonization by administering
 bacteriophage compositions
 INVENTOR(S): Morris, J. Glenn; Alavidze, Zemphira; Sulakvelidze,
 Alexander; Pasternack, Gary R.; Brown, Torrey C.
 PATENT ASSIGNEE(S): Intralytix, Inc., USA
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051066	A2	20010719	WO 2001-US809	20010111 <--
WO 2001051066	A3	20020110		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2430498	A1	20010719	CA 2001-2430498	20010111 <--
US 2002015720	A1	20020207	US 2001-757704	20010111 <--
US 6703040	B2	20040309		
EP 1250143	A2	20021023	EP 2001-922226	20010111 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004029250	A1	20040212	US 2001-757687	20010111 <--
US 6699701	B2	20040302		
EP 1421855	A2	20040526	EP 2003-79196	20010111 <--
EP 1421855	A3	20040714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2005175991	A1	20050811	US 2003-655217	20030905 <--
US 2004247569	A1	20041209	US 2003-724900	20031202 <--
US 2004191224	A1	20040930	US 2003-733064	20031211 <--
US 2004208853	A1	20041021	US 2003-732954	20031211 <--
US 2005244383	A1	20051103	US 2005-173082	20050701 <--
AU 2006245214	A1	20061221	AU 2006-245214	20061128 <--
PRIORITY APPLN. INFO.:				
			US 2000-175377P	P 20000111 <--
			US 2000-175415P	P 20000111 <--
			US 2000-175416P	P 20000111 <--
			US 2000-205240P	P 20000519 <--
			AU 2001-230889	A 20010111 <--
			AU 2001-30889	A3 20010111 <--
			EP 2001-903016	A3 20010111 <--
			US 2001-757685	B1 20010111 <--
			US 2001-757686	B1 20010111 <--
			US 2001-757687	A3 20010111 <--
			WO 2001-US809	W 20010111 <--
			US 2003-733064	A1 20031211


AB The present invention provides a method for reducing the risk of bacterial
 infection or sepsis in a susceptible patient by treating the susceptible
 patient with a pharmaceutical composition containing bacteriophage of one or

more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacterial subject to infection by said bacteriophage. For example, vancomycin-resistant Enterococcus (VRE) phage were isolated from raw sewage. A broth culture which produced the maximum yield of bacteriophage was grown in a petri dish, the top layer with the phage was scraped, mixed with a broth to obtain a suspension and the bacteriophage were isolated and purified by ion exchange chromatog. A mouse model was used to demonstrate efficacy of lytic bacteriophage in reducing VRE gastrointestinal colonization. The colonization was reduced by at least 3 logs.

IC ICM A61K035-00
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1, 62
 IT AIDS (disease)
 Antibacterial agents
 Antiulcer agents
 Bactericide resistance
 Bacteriophage
 Carcinoma
 Cystic fibrosis
 Dentifrices
 Electric apparatus
 Escherichia coli
 Haemophilus
 Klebsiella
 Leukemia
 Lymphoma
 Multidrug resistance
 Neisseria
 Pathogenic bacteria
 Proteus (bacterium)
 Respirators
 Sarcoma
 Sepsis
 Streptococcus pneumoniae
 Telephones
 Wound
 Wound healing promoters
 (bacteriophage compns. for reduction of bacterial colonization in immunocompromised patients and in medical facility)
 IT 61-32-5, Methicillin 1404-90-6, Vancomycin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (resistance; bacteriophage compns. for reduction of bacterial colonization in immunocompromised patients and in medical facility)
 IT 1404-90-6, Vancomycin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (resistance; bacteriophage compns. for reduction of bacterial colonization in immunocompromised patients and in medical facility)
 RN 1404-90-6 CAPLUS
 CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1 - B

~~— Bu-i~~

PAGE 2-A



TITLE: Cathelicidin-derived peptides with broad spectrum antimicrobial activity

INVENTOR(S): Tack, Brian E.; McCray, Paul; Welsh, Michael; Travis, Sue M.; Lehrer, Robert

PATENT ASSIGNEE(S): University of Iowa Research Foundation, USA; The Regents of the University of California

SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012668	A1	20010222	WO 2000-US22781	20000818 <--
WO 2001012668	A9	20020718		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 7071293	B1	20060704	US 2000-642744	20000818 <--
------------	----	----------	----------------	--------------

PRIORITY APPLN. INFO.:	US 1999-149886P	P 19990818 <--
------------------------	-----------------	----------------

AB The invention relates to the use of antimicrobial peptides in the inhibition of microbial growth and proliferation. Antimicrobial truncated peptides are disclosed which are based on SMAP 29 and RCAP 18, but which contain a lesser number of amino acid residues yet still retain bactericidal activity. In addition, synthetic peptides based upon the SMAP 29 protein are disclosed which have fewer amino acid residues and include substitutions yet retain substantial activity. The invention also relates to a method of inhibiting microbial growth by administering an effective amount of a peptide in accordance with the invention, or by combining the peptides with other antimicrobial agents or antibiotics.

IC ICM C07K014-47
ICS C07K007-08; A61K038-17; A61P031-04

CC 1-5 (Pharmacology)

IT Alcaligenes
Alcaligenes xylosoxidans
Anti-AIDS agents
Antibacterial agents
Antimicrobial agents
Antiviral agents
Burkholderia cepacia
Drug delivery systems
Drug resistance
Enterococcus faecalis
Enterococcus faecium
Equine infectious anemia virus
Escherichia coli
Human herpesvirus
Human immunodeficiency virus
Listeria monocytogenes
Mannheimia haemolytica
Neisseria gonorrhoeae
Pseudomonas aeruginosa
Staphylococcus aureus

Staphylococcus epidermidis
 Stenotrophomonas maltophilia
 Xanthomonas

(cathelicidin-derived peptides with broad spectrum antimicrobial activity)

IT 61-32-5, Methicillin 1404-90-6, Vancomycin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance to; cathelicidin-derived peptides with broad spectrum antimicrobial activity)

IT 1404-90-6, Vancomycin


RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance to; cathelicidin-derived peptides with broad spectrum antimicrobial activity)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— Bu-i



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:725476 CAPLUS Full-text
 DOCUMENT NUMBER: 133:291106
 TITLE: Immunomodulating polymers
 INVENTOR(S): Tzianabos, Arthur O.; Kasper, Dennis L.; Onderdonk, Andrew B.; Wang, Ying
 PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059515	A2	20001012	WO 2000-US8586	20000331 <--
WO 2000059515	A3	20010111		
WO 2000059515	A9	20020829		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2366895	A1	20001012	CA 2000-2366895	20000331 <--
AU 200040563	A	20001023	AU 2000-40563	20000331 <--
AU 781950	B2	20050623		
BR 2000009531	A	20011226	BR 2000-9531	20000331 <--
EP 1169045	A2	20020109	EP 2000-919958	20000331 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541113	T	20021203	JP 2000-609078	20000331 <--
EP 1459757	A1	20040922	EP 2004-14020	20000331 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY

US 7083777	B1	20060801	US 2000-540024	20000331 <--
MX 2001PA09930	A	20030714	MX 2001-PA9930	20011001 <--
US 2004209818	A1	20041021	US 2004-848779	20040519 <--
US 7026285	B2	20060411		
AU 2005201963	A1	20050602	AU 2005-201963	20050510 <--
US 2006153832	A1	20060713	US 2006-385111	20060321 <--

PRIORITY APPLN. INFO.:

US 1999-127584P	P	19990402 <--
US 1999-162457P	P	19991029 <--
AU 2000-40563	A3	20000331 <--
EP 2000-919958	A3	20000331 <--
US 2000-540024	A3	20000331 <--
WO 2000-US8586	W	20000331 <--

AB Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. The methods of the invention are accomplished using an immunomodulator which is a polymer having at least two repeating charge motifs separated by at least a certain min. distance.

IC ICM A61K031-7088

ICS A61K038-00; A61K038-20; A61K039-395; A61P037-02

CC 1-7 (Pharmacology)

Section cross-reference(s): 63

IT AIDS (disease)

Abscess

Antibacterial agents

Immunomodulators

Immunostimulants

Immunosuppressants

Infection

Melanoma

Molecular weight distribution

Oxidizing agents

Repeat motifs (protein)

Surgery

Zwitterions

(immunomodulating polymers)

IT 56-75-7, Chloramphenicol 61-32-5, Methicillin 61-33-6, Penicillin g, biological studies 61-72-3, Cloxacillin 66-79-5, Oxacillin 69-53-4, Ampicillin 87-08-1, Penicillin v 114-07-8, Erythromycin 147-52-4, Nafcillin 154-21-2, Lincomycin 443-48-1, Metronidazole 1404-04-2, Neomycin 1404-90-6, Vancomycin 3116-76-5, Dicloxacillin 3485-14-1, Cyclacillin 3511-16-8, Hetacillin 4697-36-3, Carbenicillin 5250-39-5, Flucloxacillin 8064-90-2 13292-46-1, Rifampin 15686-71-2, Cephalexin 18323-44-9, Clindamycin 20556-18-7 25953-19-9, Cefazolin 26774-90-3, Epicillin 26787-78-0, Amoxicillin 32887-01-7, Amdinocillin 33817-20-8, Pivampicillin 34444-01-4, Cefamandole 34787-01-4, Ticarcillin 35607-66-0, Cefoxitin 37091-66-0, Azlocillin 38821-53-3, Cephadrine 50370-12-2, Cefadroxil 50972-17-3, Bacampicillin 51481-65-3, Mezlocillin 53994-73-3, Cefaclor 56979-41-0 56979-46-5 58001-44-8 61270-58-4, Cefonicid 61477-96-1, Piperacillin 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 64221-86-9, Imipenem 64544-07-6, Cefuroxime axetil 64952-97-2, Moxalactam 65085-01-0, Cefmenoxime 68373-14-8, Sulbactam 68401-81-0, Ceftizoxime 69712-56-7, Cefotetan 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 84290-27-7, Tucaresol 86482-18-0, Timentin 266997-84-6 266998-00-9 266998-03-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunomodulating polymers)

IT 1404-90-6, Vancomycin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses).


(immunomodulating polymers)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



L46 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:390368 CAPLUS Full-text

DOCUMENT NUMBER: 131:39760

TITLE: Methods for treatment of neuro- and nephro-disorders and therapeutic toxicities using amifostine and other aminothiols compounds

INVENTOR(S): Stogniew, Martin; Alberts, David S.; Kaplan, Edward H.

PATENT ASSIGNEE(S): U.S. Bioscience, Inc., USA; The Arizona Board of Regents

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929312	A1	19990617	WO 1998-US26096	19981209 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 5994409	A	19991130	US 1997-987550	19971209 <--
CA 2313089	A1	19990617	CA 1998-2313089	19981209 <--
AU 9917184	A	19990628	AU 1999-17184	19981209 <--
AU 739068	B2	20011004		
EP 1039887	A1	20001004	EP 1998-962011	19981209 <--
EP 1039887	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2001525359	T	20011211	JP 2000-523983	19981209 <--
BR 9813524	A	20020219	BR 1998-13524	19981209 <--
EP 1537861	A2	20050608	EP 2005-3650	19981209 <--

EP 1537861 A3 20050615

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY

AT 326956	T	20060615	AT 1998-962011	19981209 <--
PT 1039887	T	20061031	PT 1998-962011	19981209 <--
ES 2260857	T3	20061101	ES 1998-962011	19981209 <--
MX 2000PA05668	A	20010219	MX 2000-PA5668	20000608 <--
JP 2006188532	A	20060720	JP 2006-64774	20060309 <--

PRIORITY APPLN. INFO.:

US 1997-987550	A	19971209 <--
EP 1998-962011	A3	19981209 <--
JP 2000-523983	A3	19981209 <--
WO 1998-US26096	W	19981209 <--

OTHER SOURCE(S): MARPAT 131:39760

AB S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate (amifostine) and other aminothiols compds. are used to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. A method is provided for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.

IC ICM A61K031-095

ICS A61K031-16

CC 1-12 (Pharmacology)

Section cross-reference(s): 63

IT Alopecia

Anti-AIDS agents

Antibiotics

Antidiabetic agents

Antihypertensives

Antitumor agents

Antiviral agents

Diabetes mellitus

Fungicides

Kidney, disease

Neoplasm

Nervous system agents

Radioprotectants

Radiotherapy

X-ray

(amifostine and other aminothiols for treatment of neuro- and nephro-disorders and therapeutic toxicities)

IT 57-22-7, Vincristine 865-21-4, Vinblastine 1397-89-3, Amphotericin B 1403-66-3, Gentamicin 1404-90-6, Vancomycin 3056-17-5, d4T 7481-89-2, DdC 8063-07-8, Kanamycin 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 30516-87-1, AZT 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 37517-28-5, Amikacin 41575-94-4, Carboplatin 69655-05-6, DdI 95058-81-4, Gemcitabine 114977-28-5, Docetaxel 125317-39-7, Navelbine 134678-17-4, 3TC

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amifostine and other aminothiols for treatment of neuro- and nephro-disorders and therapeutic toxicities)

IT 1404-90-6, Vancomycin

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(amifostine and other aminothiols for treatment of neuro- and nephro-disorders and therapeutic toxicities)

RN 1404-90-6. CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:689249 CAPLUS Full-text
 DOCUMENT NUMBER: 129:270605
 TITLE: Medicament based on singlet oxygen-producing agent
 INVENTOR(S): Stief, Thomas W.
 PATENT ASSIGNEE(S): Germany
 SOURCE: Ger. Offen., 6 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19712565	A1	19981001	DE 1997-19712565	19970325 <--
PRIORITY APPLN. INFO.:			DE 1997-19712565	19970325 <--

AB Substances which can give rise to singlet O and/or photons without excitation by irradiation are useful for treatment of diseases susceptible to singlet O or phototherapy, and can be used as anti-infective (especially antiviral) agents, immunostimulants, antithrombotics, and/or cytostatic agents. Viruses with a high concentration of cholesterol in the envelope, e.g. HIV, are especially susceptible to these agents. The agents may therefore be used for treating blood or blood products to inactivate viruses. Singlet O-generating substances can be stabilized by use as prodrugs or by addition of stabilizers such as taurine, carbonate salts, or mono- or oligosaccharides. Thus, N-chlorotaurine showed antithrombotic activity, as shown by dose-dependent prolongation of the thrombin, prothrombin, and activated partial thromboplastin times of citrated human plasma in vitro on addition of 2.5 or 3.3 mM N-chlorotaurine. N-chlorotaurine at 1 mM caused >1000-fold inactivation of HIV in whole blood within 15 min.

IC ICM A61K041-00
 ICS A61K033-02

CC 1-5 (Pharmacology)

IT Anti-infective agents
 Anticoagulants
 Antioxidants
 Antiviral agents
 Blood
 Blood plasma
 Blood products
 Cytotoxic agents
 Disinfectants
 Fibrinolytics
 Hepatitis B virus
 Hepatitis C virus
 Human herpesvirus
 Human immunodeficiency virus
 Immunostimulants
 Luminescent substances
 Oxidizing agents
 Photoconductors
 Stabilizing agents
 (medicament based on singlet oxygen-producing agent)

IT 107-35-7, Taurine 127-52-6, Chloramine B 127-65-1, Chloramine T 1404-90-6, Vancomycin 7681-52-9, Sodium hypochlorite 7790-92-3D, Hypochlorous acid, salts 23155-02-4, Phosphomycin 51036-13-6, N-Chlorotaurine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicament based on singlet oxygen-producing agent)

IT 1404-90-6, Vancomycin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(medicament based on singlet oxygen-producing agent)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:618371 CAPLUS Full-text

DOCUMENT NUMBER: 129:255004

TITLE: Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compositions therefor

INVENTOR(S): Thomas, Peter G.

PATENT ASSIGNEE(S): Cytos Pharmaceuticals LLC, USA

SOURCE: U.S., 10 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5811446	A	19980922	US 1997-839805	19970418 <--
WO 9847366	A1	19981029	WO 1998-US7319	19980417 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9873583	A	19981113	AU 1998-73583	19980417 <--
PRIORITY APPLN. INFO.:			US 1997-839805	A 19970418 <--
			WO 1998-US7319	W 19980417 <--

AB Methods are provided for protecting the eye from degenerative eye conditions by administering prophylactic histidine compns. Also provided are for treating ocular inflammation resulting from various causative agents, by administering therapeutic histidine compns. Further provided are histidine compns. for carrying out the methods.

IC ICM A01N043-50

ICS C07D233-60
 INCL 514399000
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 62, 63
 IT Adenoviridae
 Arbovirus
 Bacteria (Eubacteria)
 Borrelia burgdorferi
 Corynebacterium diphtheriae
 Cytomegalovirus
 DNA viruses
 Fungi
 Haemophilus
 Human enterovirus 70
 Human herpesvirus 1
 Human herpesvirus 2
 Human herpesvirus 3
 Human herpesvirus 4
 Human immunodeficiency virus
 Human poliovirus
 Influenza virus
 Measles virus
 Moraxella
 Mumps virus
 Neisseria gonorrhoeae
 Neisseria meningitidis
 Papillomavirus
 Parasite
 Pseudomonas
 RNA viruses
 Rabies virus
 Rhinovirus
 Serratia marcescens
 Staphylococcus
 Staphylococcus aureus
 Staphylococcus epidermidis
 Streptococcus
 (infection, eye inflammation related to; histidine compns. and methods
 for ocular degenerative diseases and inflammations)
 IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone
 50-81-7, Ascorbic acid, biological studies 51-55-8, Atropine, biological
 studies 51-83-2, Carbachol 53-03-2, Prednisone 53-86-1, Indomethacin
 54-42-2, Idoxuridine 56-75-7, Chloramphenicol 57-47-6, Physostigmine
 59-02-9, α -Tocopherol 59-42-7, Phenylephrine 59-66-5,
 Acetazolamide 69-53-4, Ampicillin 70-00-8, Trifluridine 70-18-8,
 Glutathione, biological studies 92-13-7, Pilocarpine 114-07-8,
 Erythromycin 127-40-2, Lutein 144-68-3, Zeaxanthin 378-44-9,
 Betamethasone 426-13-1, Fluorometholone 472-61-7, Astaxanthin
 514-78-3, Canthaxanthin 616-91-1, Acetyl cysteine 738-70-5,
 Trimethoprim 768-94-5, Amantadine 1403-66-3, Gentamycin
 1404-90-6, Vancomycin 1405-87-4, Bacitracin 1406-05-9,
 Penicillin 1406-11-7, Polymyxin 1695-77-8, Spectinomycin 4697-36-3,
 Carbenicillin 5104-49-4, Flurbiprofen 5536-17-4, Vidarabine
 7235-40-7, β -Carotene 7761-88-8, Silver nitrate, biological studies
 7783-00-8, Selenious acid 9054-89-1, Superoxide dismutase 11111-12-9,
 Cephalosporin 13292-46-1, Rifampin 13392-28-4, Rimantadine
 13410-01-0, Sodium selenate 15307-86-5, Diclofenac 18323-44-9,
 Clindamycin 22071-15-4, Ketoprofen 25953-19-9, Cefazolin 26787-78-0,
 Amoxicillin 26921-17-5, Timolol maleate 30516-87-1, Azidothymidine
 32986-56-4, Tobramycin 34787-01-4, Ticarcillin 51481-65-3, Mezlocillin

56272-24-3, Histidine hydrochloride 59277-89-3, Acyclovir 68767-14-6,
 Loxoprofen 70458-96-7, Norfloxacin 74103-06-3, Ketorolac 82410-32-0,
 Ganciclovir 82419-36-1, Ofloxacin 82768-44-3 85721-33-1,
 Ciprofloxacin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(histidine compns. and methods for ocular degenerative diseases and inflammations)

IT 1404-90-6, Vancomycin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(histidine compns. and methods for ocular degenerative diseases and inflammations)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:527193 CAPLUS Full-text

DOCUMENT NUMBER: 129:166193

TITLE: Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix

INVENTOR(S): Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil

PATENT ASSIGNEE(S): United States Dept. of the Army, USA; Van Hamont, John E.; et al.

SOURCE: PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 17

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832427	A1	19980730	WO 1998-US1556	19980127 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6309669	B1	20011030	US 1997-789734	19970127 <--
AU 9863175	A	19980818	AU 1998-63175	19980127 <--
PRIORITY APPLN. INFO.:			US 1997-789734	A 19970127 <--
			US 1984-590308	B1 19840316 <--
			US 1992-867301	A2 19920410 <--
			US 1995-446148	A2 19950522 <--

US 1995-446149

B2 19950522 <--

US 1996-590973

B2 19960124 <--

WO 1998-US1556

W 19980127 <--

AB Novel burst-free, sustained release biocompatible and biodegradable microcapsules are disclosed which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiol. environment. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

IC ICM A61K009-52
ICS A61K047-30

CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 2, 15

IT AIDS (disease)
Acinetobacter
Actinomycetales
Adenoviridae
Adrenoceptor agonists
Aerococcus
Aeromonas
Allergy inhibitors
Alzheimer's disease
Analgesics
Anesthetics
Angiogenesis
Angiogenesis inhibitors
Anthelmintics
Anti-infective agents
Anti-inflammatory agents
Antiarrhythmics
Antiarthritics
Antibacterial agents
Antibiotics
Anticholesteremic agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antidiarrheals
Antiemetics
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiparkinsonian agents
Antipyretics
Antirheumatic agents
Antiserums
Antitumor agents
Antitussives
Antiulcer agents
Antiviral agents
Appetite depressants
Arbovirus
Arcanobacterium haemolyticum
Arenavirus
Asthma
Bacillus (bacterium genus)

Biocompatibility
Blood substitutes
Bordetella
Borrelia
Bronchodilators
Brucella
Cachexia
Calymmatobacterium
Campylobacter
Cardiopulmonary bypass
Cardiotonics
Cardiovascular agents
Cholinergic agonists
Clostridium
Contraceptives
Coronavirus
Corynebacterium
Cryptosporidium parvum
Cystic fibrosis
Cytomegalovirus
Cytotoxic agents
Decongestants
Diagnosis
Diarrhea
Dissolution rate
Diuretics
Drug bioavailability
Drug dependence
Ebola virus
Echinococcus
Electrolytes, biological
Emulsifying agents
Enterobacteriaceae
Enterococcus
Enterovirus
Epitopes
Erysipelothrix
Expectorants
Filovirus
Flavobacterium
Freeze drying
Fungicides
Gardnerella
Gram-negative bacteria
Gram-positive bacteria (Firmicutes)
Haemophilus
Haemophilus ducreyi
Helicobacter
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Human herpesvirus 3
Human herpesvirus 4
 Human immunodeficiency virus
 Human immunodeficiency virus 1
Human parainfluenza virus
Human poliovirus
Hypercholesterolemia
Hypnotics and Sedatives
Immunization

Immunomodulators
Immunostimulants
Infection
Influenza virus
Kidney, disease
Lactococcus
Legionella
Leptospira
Leuconostoc
Listeria
Measles virus
Melanoma
Micrococcus
Molluscum contagiosum virus
Moraxella
Multiple sclerosis
Mumps virus
Muscle relaxants
Narcotics
Neisseria
Nervous system agents
Nutrients
Opioid antagonists
Osteoarthritis
Osteomyelitis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Papillomavirus
Parasitocides
Parkinson's disease
Pediococcus
Planococcus (bacterium)
Plesiomonas
Pneumonia
Poxviridae
Pseudomonas
Psoriasis
Psychotropics
Rabies virus
Reoviridae
Respiratory syncytial virus
Rheumatoid arthritis
Rhinovirus
Rhodococcus
Rotavirus
Rothia (bacterium)
Rubella virus
Salmonella typhi
Sexually transmitted diseases
Shigella boydii
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Spirillum
Staphylococcus
Streptobacillus
Streptococcus
Thrombosis
Tranquilizers

Treponema
 Vaccines
 Vasodilators
 Vibrio
 Vibrio cholerae
 Wolinella succinogenes
 Yersinia

(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin
 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8,
 Prednisolone 50-28-2, 17 β -Estradiol, biological studies 50-33-9,
 Phenylbutazone, biological studies 50-52-2, Thioridazine 50-55-5,
 Reserpine 50-78-2, Aspirin 51-55-8, Atropine, biological studies
 52-24-4, Thiotepe 52-76-6, Lynestrenol 53-03-2, Prednisone 53-16-7,
 Estrone, biological studies 53-86-1, Indomethacin 54-11-5, Nicotine
 55-48-1, Atropine sulfate 55-63-0, Nitroglycerin 55-86-7, Nitrogen
 mustard 56-53-1, Diethyl stilbestrol 56-75-7, Chloramphenicol
 57-27-2, Morphine, biological studies 57-33-0, Sodium pentobarbital
 57-42-1, Meperidine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol
 57-85-2, Testosterone propionate 57-92-1, Streptomycin a, biological
 studies 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine
 58-22-0 58-25-3, Chlordiazepoxide 58-39-9, Perphenazine 58-73-1,
 Diphenhydramine 59-01-8, Kanamycin a 59-05-2, Methotrexate 59-92-7,
 L-Dopa, biological studies 61-33-6, Penicillin g, biological studies
 67-20-9, Nitrofurantoin 68-22-4, Norethisterone 68-23-5, Norethynodrel
 69-09-0, Chlorpromazine hydrochloride 69-53-4, Ampicillin 69-72-7D,
 Salicylic acid, derivs. 71-58-9, Medroxyprogesterone acetate 72-33-3,
 Mestranol 76-57-3, Codeine 79-57-2, Oxytetracycline 79-64-1,
 Dimethisterone 91-81-6, Tripeleminamine 103-90-2, Acetaminophen
 113-15-5, Ergotamine 114-07-8, Erythromycin 114-49-8, Hyoscyne
 hydrobromide 121-54-0 122-09-8, Phentermine 125-29-1,
 Dihydrocodeinone 125-71-3, Dextromethorphan 127-48-0, Trimethadione
 128-62-1, Noscapine 145-94-8, Chlorindanol 148-82-3, Melphalan
 155-41-9, Methscopolamine bromide 288-32-4D, Imidazole, derivs.
 297-76-7, Ethynodiol diacetate 302-22-7, Chlormadinone acetate
 305-03-3, Chlorambucil 309-43-3, Sodium secobarbital 315-30-0,
 Allopurinol 434-03-7, Ethisterone 439-14-5, Diazepam 443-48-1,
 Metronidazole 469-62-5 471-34-1, Calcium carbonate, biological studies
 497-19-8, Sodium carbonate, biological studies 523-87-5, Dimenhydrinate
 546-93-0, Magnesium carbonate 578-66-5D, 8-Aminoquinoline, derivs.
 578-68-7D, 4-Aminoquinoline, derivs. 595-33-5, Megestrol acetate
 738-70-5, Trimethoprim 846-50-4, Temazepam 1397-89-3, Amphotericin b
 1397-94-0, Antimycin a 1403-66-3, Gentamicin 1404-26-8, Polymyxin b
 1404-90-6, Vancomycin 1406-05-9D, Penicillin, derivs.
 4696-76-8, Kanamycin b 5588-33-0, Mesoridazine 5633-18-1, Melengestrol
 5786-21-0, Clozapine 5800-19-1, Metiapine 6533-00-2, Norgestrel
 7447-40-7, Potassium chloride (KCl), biological studies 8063-07-8,
 Kanamycin 9000-83-3, Atpase 9000-92-4, Amylase 9001-62-1, Lipase
 9001-63-2, Muramidase 9001-67-6, Neuraminidase 9001-78-9, Alkaline
 phosphatase 9001-99-4, Ribonuclease 9002-02-2, Succinic acid
 dehydrogenase 9002-07-7, Trypsin 9004-07-3, Chymotrypsin 9004-10-8,
 Insulin, biological studies 9025-82-5, Phosphodiesterase 9029-12-3,
 Glutamic acid dehydrogenase 9035-74-9, Glycogen phosphorylase
 9046-27-9, γ -Glutamyltranspeptidase 9079-67-8 10118-90-8,
 Minocycline 11111-12-9, Cephalosporins 13292-46-1, Rifampin
 14271-04-6 21645-51-2, Aluminum hydroxide, biological studies
 22232-71-9, Mazindol 24730-10-7, Dihydroergocristine methanesulfonate
 25447-66-9 26780-50-7, Poly(lactide co-glycolide) 26787-78-0,
 Amoxicillin 30516-87-1, Azt 32986-56-4, Tobramycin 35189-28-7,

Norgestimate 37205-61-1, Proteinase inhibitor 37517-28-5, Amikacin
 53678-77-6D, Muramyl dipeptide, derivs. 53994-73-3, Cefaclor
 55268-75-2, Cefuroxime 61036-62-2, Teicoplanin 64221-86-9, Imipenem
 80738-43-8, Lincosamide 81103-11-9, Clarithromycin 82419-36-1,
 Ofloxacin 85721-33-1, Ciprofloxacin

RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
 (Device component use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PROC (Process); USES (Uses)

(prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric matrix)

IT 1404-90-6, Vancomycin

RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
 (Device component use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PROC (Process); USES (Uses)


(prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric matrix)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:31330 CAPLUS Full-text

DOCUMENT NUMBER: 128:97702

TITLE: TNF-derived peptides having neutrophil and/or monocyte/macrophage stimulatory activity for prevention and treatment of infection

INVENTOR(S): Rathjen, Deborah Ann; Sleigh, Joy Merilyn; Mack, Philip On-Lok; Widmer, Fred

PATENT ASSIGNEE(S): Peptech Ltd., Australia; Rathjen, Deborah Ann; Sleigh, Joy Merilyn; Mack, Philip On-Lok; Widmer, Fred

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748725	A1	19971224	WO 1997-AU395	19970620 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9730842	A	19980107	AU 1997-30842	19970620 <--
ZA 9705500	A	19981221	ZA 1997-5500	19970620 <--
PRIORITY APPLN. INFO.:			AU 1996-610	A 19960621 <--
			AU 1996-2165	A 19960906 <--
			AU 1996-3309	A 19961029 <--
			WO 1997-AU395	W 19970620 <--

OTHER SOURCE(S): MARPAT 128:97702

- AB Peptides of 8 to 15 amino acids in length are described which possess neutrophil and/or monocyte/macrophage stimulatory activity. The peptides may be used in methods of treatment of various diseases and conditions in which enhancement of neutrophil and/or monocyte/macrophage function is desirable. The peptides are X1-X2-X3-X4-Ser-Thr-X5-Val-X6-Ile-Thr-X7-X8-X9-X10 [X1 = absent, Cys, R1; X2 = absent, Ala, Arg, Glu, Gly; X3 = absent, Ala, Arg, Asn, Cys, Glu, Gly, His, Ile, Leu, Lys, Met, Pro, Ser, Trp, γ -Abu, β Ala, Dbu, Sar, Suc, N-Me-Ala; X4 = absent, Ala, Arg, Asn, Glu, His, Leu, Lys, Met, Pro, Ser, Trp, β Ala, Nip; X5 = Ala, His; X6 = Ala, Gly, Ile, Leu, Phe, Pro, Ser, Thr, Trp, Val, D-Ala, D-Ile, D-Pro, D-Ser, D-Thr, D-Val, β Ala; X7 = His or Ala; X8 = absent, Ile, Leu, Thr, D-Ile; X9 = absent, Ile, D-Ile, Aib; X10 = absent, Cys, R2; R1 = H, RCO (R = C1-20 straight-chain, branched, or cyclic alkyl (optionally substituted and with optional double bonds)), glycosyl, nucleosyl, lipoyl, or R1 is absent when adjacent amino acid is unsubstituted desamino derivative; R2 = NR12R13 (R12, R13 = H, optionally substituted straight-chain, branched, or cyclic alkyl, aralkyl, or aryl), N-glycosyl, etc.]. The peptides are derived from a portion of the TNF sequence. The peptides may be used in combination therapy with other agents.
- IC ICM C07K007-06
ICS C07K007-08; C07K007-10; A61K037-02
- CC 1-5 (Pharmacology)
Section cross-reference(s): 15
- IT AIDS (disease)
Cystic fibrosis
Diabetes mellitus
Leukemia
Lymphoma
Neoplasm
Paroxysmal nocturnal hemoglobinuria
Tuberculosis
(infection treatment in; TNF-derived peptides having neutrophil and/or monocyte/macrophage stimulatory activity for prevention and treatment of infection, and combinations with other agents)
- IT 50-18-0, Cyclophosphamide 50-24-8 50-44-2, Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 54-85-3, Isoniazid 55-98-1, Busulfan 60-54-8, Tetracycline 66-79-5, Oxacillin 69-53-4, Ampicillin 69-74-9, Cytarabine hydrochloride 74-55-5, Ethambutol 98-96-4, Pyrazinamide 114-07-8, Erythromycin 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 147-52-4, Nafcillin 148-82-3, Melphalan 154-93-8, Carmustine 305-03-3, Chlorambucil 320-67-2, Azacitidine 366-70-1, Procarbazine hydrochloride 443-48-1, Metronidazole 564-25-0, Doxycycline 645-05-6, Hexamethylmelamine 1397-89-3, Amphotericin B 1403-66-3, Gentamycin 1404-00-8, Mitomycin 1404-90-6, Vancomycin 1406-05-9, Penicillin 2022-85-7, Flucytosine 3778-73-2, Ifosfamide 4342-03-4, Dacarbazine 11111-12-9, Cephalosporin 13010-47-4, Lomustine 13292-46-1, Rifampin 14769-73-4, Levamisole 15663-27-1, Cisplatin 18323-44-9, Clindamycin 18378-89-7, Plicamycin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 32986-56-4, Tobramycin 33419-42-0, Etoposide 34787-01-4, Ticarcillin 35607-66-0, Cefoxitin 37517-28-5, Amikacin 41575-94-4, Carboplatin 51264-14-3, Amsacrine 53910-25-1, Deoxycoformycin 56391-56-1, Netilmicin 59277-89-3, Acyclovir 59865-13-3, Cyclosporin A 64221-86-9, Imipenem 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 72559-06-9, Rifabutin 78110-38-0, Aztreonam 81103-11-9, Clarithromycin 82410-32-0, Ganciclovir 83869-56-1, Granulocyte-macrophage colony-stimulating factor 83905-01-5, Azithromycin 143011-72-7, Granulocyte colony-stimulating factor
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TNF-derived peptides having neutrophil and/or monocyte/macrophage stimulatory activity for prevention and treatment of infection, and combinations with other agents).

IT 1404-90-6, Vancomycin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(TNF-derived peptides having neutrophil and/or monocyte/macrophage stimulatory activity for prevention and treatment of infection, and combinations with other agents)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—Bu-i



L46 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:281150 CAPLUS Full-text

DOCUMENT NUMBER: 126:260137

TITLE: Targeting of proteins to the cell wall of gram-positive bacteria

INVENTOR(S): Schneewind, Olaf; Baba, Tadashi

PATENT ASSIGNEE(S): Regents of the University of California, USA

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9708553	A1	19970306	WO 1996-US14154	19960822 <--
W: AU, BR, CA, IL, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9669133	A	19970319	AU 1996-69133	19960822 <--
PRIORITY APPLN. INFO.:			US 1995-2615P	P 19950822 <--
			WO 1996-US14154	W 19960822 <--

OTHER SOURCE(S): MARPAT 126:260137


AB A method of stable noncovalent display of proteins, peptides, or compds. covalently linked to proteins or peptides on the surface of gram-pos. bacteria provides advantages over phage display. One embodiment of the present invention comprises a method for noncovalent protein targeting, comprising the steps of: (1) cloning a nucleic acid segment encoding a chimeric protein into a gram-pos. bacterium to generate a cloned chimeric protein including therein a carboxyl-terminal cell-wall targeting signal; (2) growing the bacterium into which the nucleic acid segment has been cloned to express the chimeric protein to generate a chimeric protein including therein a carboxyl-terminal cell-wall targeting signal; and (3) binding the expressed chimeric protein noncovalently and stably to the cell-wall via the carboxyl-terminal cell-wall targeting signal so that the chimeric protein is displayed on the surface on the gram-pos. bacterium in such a way that the protein is accessible to a ligand. Alternatively, the chimeric protein can be produced by expression in another expression system and contacted with the gram-pos. bacterium. Described are

methods for producing vaccines as well as for using antibiotic-protein conjugates to treat infections.

- IC ICM G01N033-53
- ICS G01N033-569; G01N033-536; G01N033-543; G01N033-566; G01N033-549;
G01N033-531; C12N001-20; C12N015-00; C12N015-63; C12N001-14;
C12N015-09; C12N015-70; C12N015-74; A61K038-00; C07K002-00;
C07K004-00; C07K005-00; C07K007-00; C07K016-00
- CC 3-2 (Biochemical Genetics)
Section cross-reference(s): 63
- IT Cell wall
Genetic vectors
Gram-positive bacteria (Firmicutes)
Human immunodeficiency virus
Infection
Microorganism
Molecular cloning
PCR (polymerase chain reaction)
Reverse transcription
Staphylococcus
Staphylococcus aureus
Staphylococcus simulans
Vaccines
Virus
(proteins targeting to cell wall of gram-pos. bacteria)
- IT 56-75-7D, Chloramphenicol, protein conjugates 57-92-1D, Streptomycin,
protein conjugates, biological studies 69-53-4D, Ampicillin, protein
conjugates 1403-66-3D, Gentamicin, protein conjugates 1404-04-2D,
Neomycin, protein conjugates 1404-90-6D, Vancomycin, protein
conjugates 1406-05-9D, Penicillin, protein conjugates 8063-07-8D,
Kanamycin, protein conjugates 11111-12-9D, Cephalosporin, protein
conjugates 13292-46-1D, Rifampin, protein conjugates 18323-44-9D,
Clindamycin, protein conjugates 32986-56-4D, Tobramycin, protein
conjugates 37517-28-5D, Amikacin, protein conjugates 70458-96-7D,
Norfloxacin, protein conjugates 84420-34-8D, Paromomycin, protein
conjugates 85721-33-1D, Ciprofloxacin, protein conjugates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(proteins targeting to cell wall of gram-pos. bacteria)
- IT 1404-90-6D, Vancomycin, protein conjugates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(proteins targeting to cell wall of gram-pos. bacteria)
- RN 1404-90-6 CAPLUS
- CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A




TITLE: Therapy of *Rhodococcus equi* disseminated infections in nude mice
 AUTHOR(S): Nordmann, Patrice; Kerestedjian, Jean Jacques; Ronco, Esthel
 CORPORATE SOURCE: Serv. Microbiol., Hop. Raymond Poincare, Garches, 92380, Fr.
 SOURCE: Antimicrobial Agents and Chemotherapy (1992), 36(6), 1244-8
 CODEN: AMACCQ; ISSN: 0066-4804
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB *Rhodococcus equi* is a facultative, intracellular, gram-pos. coccobacillus increasingly reported as an opportunistic pathogen in human immunodeficiency virus-pos. patients. However, the optimal drug regimen for treating *R. equi* pulmonary or systemic infections is not yet known. Therefore, a model of i.v. infected nude mice with disseminated infection was created to study the efficacy of antibiotics alone or in combination as determined by the reduction of bacterial CFU per g in the lungs and spleen after 4 and 11 days of treatment. The studied antibiotics possessing low MICs against *R. equi* strains were amikacin, ciprofloxacin, erythromycin, imipenem, minocycline, rifampin, and vancomycin. Vancomycin, imipenem, and rifampin were the most effective agents in monotherapy. On the other hand, amikacin, ciprofloxacin, erythromycin, and minocycline alone were not active in this model. The most active drug combinations were those including vancomycin. No antibiotic-resistant mutants were selected in vivo with treatment involving any drugs used alone or in combination. Although the treatment recommended until now for *R. equi* infections is rifampin plus erythromycin, this study suggests that antibiotic combinations which include vancomycin may be the most effective in vivo.

CC 1-5 (Pharmacology)
 IT Acquired immune deficiency syndrome
 (Rhodococcus equi infection in, antibiotics treatment of)
 IT 114-07-8, Erythromycin 1404-90-6, Vancomycin 10118-90-8,
 Minocycline 13292-46-1, Rifampin 37517-28-5, Amikacin 64221-86-9,
 Imipenem 85721-33-1, Ciprofloxacin
 RL: BIOL (Biological study)
 (Rhodococcus equi infection treatment by)
 IT 1404-90-6, Vancomycin
 RL: BIOL (Biological study)
 (Rhodococcus equi infection treatment by)
 RN 1404-90-6 CAPLUS
 CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



TITLE: Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome

AUTHOR(S): Yajko, David M.; Nassos, Patricia S.; Hadley, W. Keith

CORPORATE SOURCE: Dep. Lab. Med., Univ. California, San Francisco, CA, 94110, USA

SOURCE: Antimicrobial Agents and Chemotherapy (1987), 31(10), 1579-84
CODEN: AMACQ; ISSN: 0066-4804

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A total of 31 strains of M. avium complex isolated from patients with acquired immune deficiency syndrome were tested for susceptibility to 30 antimicrobial agents by using microdilution trays containing dried antimicrobial agents. MICs were determined over a period of 7 days of growth in a broth medium (7HSF) that is equivalent to 7H11 agar. MICs obtained by this method showed good agreement with MICs determined by the agar dilution method. Strains could be divided into two groups by their antimicrobial susceptibility patterns. All group 1 strains (8 of the 31 strains tested) were at least moderately susceptible to inhibition by a variety of β -lactam antimicrobial agents, including amoxicillin-clavulanic acid and cefmenoxime. Group 2 strains (23 of 31) were susceptible only to amikacin (22 of 23 strains). All 31 strains were resistant to oxacillin, clindamycin, erythromycin, tetracycline, chloramphenicol, vancomycin, nitrofurantoin, and aztreonam at the highest concentration of antimicrobial agent present in the microdilution trays. The addition of Tween 80 to 7HSF broth increased the susceptibility of M. avium complex to many of the antimicrobial agents tested. Killing of M. avium complex (i.e., $\leq 1\%$ survival after 7 days) was found to vary for different strains and antimicrobial agents. Killing of some strains by amoxicillin-clavulanic acid, carbenicillin, azlocillin, cefmenoxime, cefotaxime, amikacin, and ampicillin occurred at concns. of antimicrobial agent that are achievable in serum. Further studies are needed to determine whether any of these antimicrobial agents has activity against M. avium complex cells that have been ingested by macrophages.

CC 10-5 (Microbial Biochemistry)

IT Immunodeficiency
(acquired immune deficiency syndrome, Mycobacterium avium from humans with, antibiotic susceptibility of)

IT 56-75-7, Chloramphenicol 60-54-8, Tetracycline 61-33-6, biological studies 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 69-53-4, Ampicillin 114-07-8, Erythromycin 153-61-7, Cephalothin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 4697-36-3, Carbenicillin 8064-90-2 18323-44-9, Clindamycin 26787-78-0, Amoxicillin 34787-01-4, Ticarcillin 37091-66-0, Azlocillin 37517-28-5, Amikacin 51481-65-3, Mezlocillin 55268-75-2, Cefuroxime 56391-56-1, Netilmicin 61270-58-4, Cefonicid 61477-96-1, Piperacillin 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 64221-86-9, Imipenem 64952-97-2, Moxalactam 65085-01-0, Cefmenoxime 68401-81-0, Ceftizoxime 73384-59-5, Ceftriaxone 78110-38-0, Aztreonam

RL: BIOL (Biological study)
(Mycobacterium avium susceptibility to)


IT 1404-90-6, Vancomycin
RL: BIOL (Biological study)
(Mycobacterium avium susceptibility to)

RN 1404-90-6 CAPLUS

CN Vancomycin (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

—Bu-i

PAGE 2-A



SPECIES SEARCH

=> fil reg;d stat que 139; fil capl; s 139
 FILE 'REGISTRY' ENTERED AT 13:10:29 ON 12 SEP 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 11 SEP 2007 HIGHEST RN 946658-01-1
 DICTIONARY FILE UPDATES: 11 SEP 2007 HIGHEST RN 946658-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


L4

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L4.str



chain nodes :

31 32 40 45 46 47

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44

ring/chain nodes :

34 35

chain bonds :

10-46 19-31 21-32 25-47 38-40 41-45

ring/chain bonds :

11-34 15-34 18-35 24-26 28-36

ring bonds :

1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 25-26 25-30 26-27 27-28 28-29 29-30 36-37 36-41 37-38 38-39 41-42
42-43 43-44

exact/norm bonds :

2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 24-26 25-47 28-36
36 36-37 36-41 37-38 38-39 38-40 41-42 41-45 42-43 43-44

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30

Match level :



1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS

L8 7166 SEA FILE=REGISTRY SSS FUL L4
L32 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L32.str



chain nodes :

31 32 40 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 65
66 67 68 69 71 72 73 74 75 76 77

```

ring nodes :
1  2  3  4  5  6  7  8  9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44 62 63 64
ring/chain nodes :
34 35
chain bonds :
6-71 10-46 16-48 19-31 20-59 21-32 25-47 35-49 38-40 39-53 41-45 44-58
49-50 49-72 50-51 50-52 53-54 54-55 54-57 55-56 59-60 60-61 62-68 64-65
65-66 65-67 66-69 72-73 73-74 73-77 74-75 75-76
ring/chain bonds :
11-34 15-34 18-35
ring bonds :
1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 23-64 24-26 25-26 25-30 26-27 27-28 28-29 28-36 29-30 36-37 36-41
37-38 38-39 41-42 42-43 43-44 43-62 62-63 63-64
exact/norm bonds :
2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 23-64 24-26 25-
47 28-36 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45 42-43 43-44
43-62 44-58 49-72 53-54 54-55 54-57 55-56 59-60 62-63 62-68 63-64 65-66
65-67 66-69 72-73 73-74 73-77 74-75
exact bonds :
6-71 16-48 20-59 35-49 49-50 60-61 64-65 75-76
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30 50-51 50-52

```

Connectivity :

56:1 E exact RC ring/chain 69:1 E exact RC ring/chain

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS
55:CLASS 56:CLASS 57:CLASS 58:CLASS 59:CLASS 60:CLASS 61:Atom 62:Atom
63:Atom 64:Atom 65:CLASS 66:CLASS 67:CLASS 68:CLASS 69:CLASS 71:CLASS
72:CLASS 73:CLASS 74:CLASS 75:CLASS 76:Atom 77:CLASS

```

Generic attributes :

61:

```

Saturation           : Saturated
Number of Carbon Atoms : 7 or more
Type of Ring System   : Polycyclic

```

76:

```

Saturation           : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System   : Monocyclic

```


L33

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L33.str



chain nodes :

31 32 40 45 46 47 48 52 55 56 57 58 59 63 64 65 66 67 69 73 74
 89 90 91 92 93 94 95 96

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
 24 25 26 27 28 29 30 33 34 35 36 37 38 39 41 42 43 44 49 50 51
 53 54 60 61 62 70 71 72 75 76 77 78 79 80 81 82 83 84 85 86 87
 88

chain bonds :

6-69 10-46 16-48 19-31 20-57 21-32 25-47 35-74 38-40 41-45 44-56 50-52
 54-55 57-58 58-59 59-92 60-66 62-63 63-64 63-65 64-67 67-96 71-73 72-90
 77-89 82-91 92-93 92-94 92-95

ring bonds :

1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
 11-12 11-34 13-14 13-18 14-15 15-16 15-34 16-17 17-18 18-35 19-20 19-24
 20-21 21-22 22-23 23-24 23-62 24-26 25-26 25-30 26-27 27-28 28-29 28-36
 29-30 35-49 36-37 36-41 37-38 38-39 39-53 41-42 42-43 43-44 43-60 49-50
 49-70 50-51 51-75 53-54 54-75 60-61 61-62 70-71 71-72 72-85 75-79 76-77
 76-81 77-78 78-79 79-80 80-81 81-88 82-83 82-87 83-84 83-88 84-85 85-86
 86-87

exact/norm bonds :

2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 20-57 21-32 23-62 24-
 26 25-47 28-36 35-49 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45
 42-43 43-44 43-60 44-56 49-50 49-70 50-51 50-52 51-75 53-54 54-55 54-75
 57-58 58-59 59-92 60-61 60-66 61-62 63-64 63-65 64-67 67-96 70-71 71-72
 71-73 72-85 72-90 75-79 77-89 81-88 82-91 83-88 92-93 92-94 92-95

exact bonds :

6-69 16-48 35-74 62-63

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
 15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
 26-27 27-28 28-29 29-30 76-77 76-81 77-78 78-79 79-80 80-81 82-83 82-87
 83-84 84-85 85-86 86-87

Connectivity :

57:2 E exact RC ring/chain 59:2 E exact RC ring/chain 67:2 E exact RC ring/chain
 93:1 E exact RC ring/chain 94:1 E exact RC ring/chain 95:1 E exact RC ring/chain
 Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
 38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
 47:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom 52:CLASS 53:Atom 54:Atom 55:CLASS
 56:CLASS 57:CLASS 58:CLASS 59:CLASS 60:Atom 61:Atom 62:Atom 63:CLASS
 64:CLASS 65:CLASS 66:CLASS 67:CLASS 69:CLASS 70:Atom 71:Atom 72:Atom
 73:CLASS 74:CLASS 75:Atom 76:Atom 77:Atom 78:Atom 79:Atom 80:Atom 81:Atom
 82:Atom 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom 88:Atom 89:CLASS 90:CLASS
 91:CLASS 92:CLASS 93:CLASS 94:CLASS 95:CLASS 96:CLASS


L34

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L34.str



chain nodes :

31 32 40 45 46 47 48 52 55 56 60 61 62 63 64 66 67 68 69 70 71
 73 74 75 77 78 79 80 81 82

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
 24 25 26 27 28 29 30 33 34 35 36 37 38 39 41 42 43 44 49 50 51
 53 54 57 58 59 72

chain bonds :

6-66 10-46 16-48 19-31 20-82 21-32 25-47 35-71 38-40 41-45 44-56 49-67
 50-52 54-55 57-63 59-60 60-61 60-62 61-64 64-74 67-68 68-69 68-70 69-73
 69-77 72-78 73-75 78-79 79-80 79-81

ring bonds :

1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
 11-12 11-34 13-14 13-18 14-15 15-16 15-34 16-17 17-18 18-35 19-20 19-24
 20-21 21-22 22-23 23-24 23-59 24-26 25-26 25-30 26-27 27-28 28-29 28-36
 29-30 35-49 36-37 36-41 37-38 38-39 39-53 41-42 42-43 43-44 43-57 49-50
 50-51 51-72 53-54 54-72 57-58 58-59

exact/norm bonds :

2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 23-59 24-26 25-
 47 28-36 35-49 35-71 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45
 42-43 43-44 43-57 44-56 49-50 49-67 50-51 50-52 51-72 53-54 54-55 54-72
 57-58 57-63 58-59 60-61 60-62 61-64 64-74 67-68 68-70 69-73 69-77 72-78

73-75 78-79 79-80 79-81

exact bonds :

6-66 16-48 20-82 59-60 68-69

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30 26-27 27-28 28-29 29-30

Connectivity :

64:2 E exact RC ring/chain 75:1 E exact RC ring/chain 77:1 E exact RC ring/chain

78:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom 52:CLASS 53:Atom 54:Atom 55:CLASS
56:CLASS 57:Atom 58:Atom 59:Atom 60:CLASS 61:CLASS 62:CLASS 63:CLASS
64:CLASS 66:CLASS 67:Atom 68:Atom 69:Atom 70:CLASS 71:CLASS 72:Atom
73:CLASS 74:CLASS 75:CLASS 77:CLASS 78:CLASS 79:CLASS 80:CLASS 81:CLASS
82:CLASS

Generic attributes :

74:

Saturation : Saturated

Number of Carbon Atoms : 7 or more

Type of Ring System : Polycyclic

L39 3 SEA FILE=REGISTRY SUB=L8 SSS FUL (L32 OR L33 OR L34)

100.0% PROCESSED 2277 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 13:10:29 ON 12 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Sep 2007 VOL 147 ISS 12

FILE LAST UPDATED: 11 Sep 2007 (20070911/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L47 4 L39

=> d scan ti

L47 4 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN

TI Glycopeptide antibiotic derivatives, their preparation and their use as
 antiviral agents

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L47 4 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN

TI Structure-Activity Relationship Studies of a Series of Antiviral and
 Antibacterial Aglycon Derivatives of the Glycopeptide Antibiotics
 Vancomycin, Eremomycin, and Dechloroeremomycin

L47 4 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN

TI Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic
 derivatives of glycopeptide antibiotics

L47 4 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN

TI Antiretroviral Activity of Semisynthetic Derivatives of Glycopeptide
 Antibiotics

ALL ANSWERS HAVE BEEN SCANNED

ALL OF THESE REFERENCES WERE DISPLAYED IN FULL AS PART OF THE INVENTORS SEARCH


SEARCH HISTORY

=> d stat que 139;d his nofile
L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L4.str



chain nodes :

31 32 40 45 46 47

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44

ring/chain nodes :

34 35

chain bonds :

10-46 19-31 21-32 25-47 38-40 41-45

ring/chain bonds :

11-34 15-34 18-35 24-26 28-36

ring bonds :

1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 25-26 25-30 26-27 27-28 28-29 29-30 36-37 36-41 37-38 38-39 41-42
42-43 43-44

exact/norm bonds :

2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 24-26 25-47 28-36
36-37 36-41 37-38 38-39 38-40 41-42 41-45 42-43 43-44

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom


38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS

L8 7166 SEA FILE=REGISTRY SSS FUL L4
L32 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L32.str



chain nodes :

31 32 40 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 65
66 67 68 69 71 72 73 74 75 76 77

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 36 37 38 39 41 42 43 44 62 63 64

ring/chain nodes :

34 35

chain bonds :

6-71 10-46 16-48 19-31 20-59 21-32 25-47 35-49 38-40 39-53 41-45 44-58
49-50 49-72 50-51 50-52 53-54 54-55 54-57 55-56 59-60 60-61 62-68 64-65
65-66 65-67 66-69 72-73 73-74 73-77 74-75 75-76

ring/chain bonds :

11-34 15-34 18-35

ring bonds :

1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23
23-24 23-64 24-26 25-26 25-30 26-27 27-28 28-29 28-36 29-30 36-37 36-41
37-38 38-39 41-42 42-43 43-44 43-62 62-63 63-64

exact/norm bonds :

2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 23-64 24-26 25-
47 28-36 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45 42-43 43-44
43-62 44-58 49-72 53-54 54-55 54-57 55-56 59-60 62-63 62-68 63-64 65-66
65-67 66-69 72-73 73-74 73-77 74-75

exact bonds :

6-71 16-48 20-59 35-49 49-50 60-61 64-65 75-76

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30

26-27 27-28 28-29 29-30 50-51 50-52

Connectivity :

56:1 E exact RC ring/chain 69:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:CLASS 35:CLASS 36:Atom 37:Atom
 38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS
 55:CLASS 56:CLASS 57:CLASS 58:CLASS 59:CLASS 60:CLASS 61:Atom 62:Atom
 63:Atom 64:Atom 65:CLASS 66:CLASS 67:CLASS 68:CLASS 69:CLASS 71:CLASS
 72:CLASS 73:CLASS 74:CLASS 75:CLASS 76:Atom 77:CLASS

Generic attributes :

61:

Saturation : Saturated

Number of Carbon Atoms : 7 or more

Type of Ring System : Polycyclic

76:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic


L33

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L33.str



chain nodes :

31 32 40 45 46 47 48 52 55 56 57 58 59 63 64 65 66 67 69 73 74
 89 90 91 92 93 94 95 96

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

24 25 26 27 28 29 30 33 34 35 36 37 38 39 41 42 43 44 49 50 51
 53 54 60 61 62 70 71 72 75 76 77 78 79 80 81 82 83 84 85 86 87
 88

chain bonds :

6-69 10-46 16-48 19-31 20-57 21-32 25-47 35-74 38-40 41-45 44-56 50-52
 54-55 57-58 58-59 59-92 60-66 62-63 63-64 63-65 64-67 67-96 71-73 72-90
 77-89 82-91 92-93 92-94 92-95

ring bonds :

1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
 11-12 11-34 13-14 13-18 14-15 15-16 15-34 16-17 17-18 18-35 19-20 19-24
 20-21 21-22 22-23 23-24 23-62 24-26 25-26 25-30 26-27 27-28 28-29 28-36
 29-30 35-49 36-37 36-41 37-38 38-39 39-53 41-42 42-43 43-44 43-60 49-50
 49-70 50-51 51-75 53-54 54-75 60-61 61-62 70-71 71-72 72-85 75-79 76-77
 76-81 77-78 78-79 79-80 80-81 81-88 82-83 82-87 83-84 83-88 84-85 85-86
 86-87

exact/norm bonds :

2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 20-57 21-32 23-62 24-
 26 25-47 28-36 35-49 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45
 42-43 43-44 43-60 44-56 49-50 49-70 50-51 50-52 51-75 53-54 54-55 54-75
 57-58 58-59 59-92 60-61 60-66 61-62 63-64 63-65 64-67 67-96 70-71 71-72
 71-73 72-85 72-90 75-79 77-89 81-88 82-91 83-88 92-93 92-94 92-95

exact bonds :

6-69 16-48 35-74 62-63

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
 15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
 26-27 27-28 28-29 29-30 76-77 76-81 77-78 78-79 79-80 80-81 82-83 82-87
 83-84 84-85 85-86 86-87

Connectivity :

57:2 E exact RC ring/chain 59:2 E exact RC ring/chain 67:2 E exact RC ring/chain
 93:1 E exact RC ring/chain 94:1 E exact RC ring/chain 95:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
 38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
 47:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom 52:CLASS 53:Atom 54:Atom 55:CLASS
 56:CLASS 57:CLASS 58:CLASS 59:CLASS 60:Atom 61:Atom 62:Atom 63:CLASS
 64:CLASS 65:CLASS 66:CLASS 67:CLASS 69:CLASS 70:Atom 71:Atom 72:Atom
 73:CLASS 74:CLASS 75:Atom 76:Atom 77:Atom 78:Atom 79:Atom 80:Atom 81:Atom
 82:Atom 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom 88:Atom 89:CLASS 90:CLASS
 91:CLASS 92:CLASS 93:CLASS 94:CLASS 95:CLASS 96:CLASS


L34

STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

Uploading L34.str



chain nodes :

31 32 40 45 46 47 48 52 55 56 60 61 62 63 64 66 67 68 69 70 71
73 74 75 77 78 79 80 81 82

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 33 34 35 36 37 38 39 41 42 43 44 49 50 51
53 54 57 58 59 72

chain bonds :

6-66 10-46 16-48 19-31 20-82 21-32 25-47 35-71 38-40 41-45 44-56 49-67
50-52 54-55 57-63 59-60 60-61 60-62 61-64 64-74 67-68 68-69 68-70 69-73
69-77 72-78 73-75 78-79 79-80 79-81

ring bonds :

1-2 1-6 2-3 2-44 3-4 4-5 5-6 5-33 7-8 7-12 7-39 8-9 9-10 9-33 10-11
11-12 11-34 13-14 13-18 14-15 15-16 15-34 16-17 17-18 18-35 19-20 19-24
20-21 21-22 22-23 23-24 23-59 24-26 25-26 25-30 26-27 27-28 28-29 28-36
29-30 35-49 36-37 36-41 37-38 38-39 39-53 41-42 42-43 43-44 43-57 49-50
50-51 51-72 53-54 54-72 57-58 58-59

exact/norm bonds :

2-44 5-33 7-39 9-33 10-46 11-34 15-34 18-35 19-31 21-32 23-59 24-26 25-
47 28-36 35-49 35-71 36-37 36-41 37-38 38-39 38-40 39-53 41-42 41-45
42-43 43-44 43-57 44-56 49-50 49-67 50-51 50-52 51-72 53-54 54-55 54-72
57-58 57-63 58-59 60-61 60-62 61-64 64-74 67-68 68-70 69-73 69-77 72-78
73-75 78-79 79-80 79-81

exact bonds :

6-66 16-48 20-82 59-60 68-69

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 25-26 25-30
26-27 27-28 28-29 29-30

Connectivity :

64:2 E exact RC ring/chain 75:1 E exact RC ring/chain 77:1 E exact RC ring/chain
78:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:Atom 30:Atom 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:CLASS 49:Atom 50:Atom 51:Atom 52:CLASS 53:Atom 54:Atom 55:CLASS
56:CLASS 57:Atom 58:Atom 59:Atom 60:CLASS 61:CLASS 62:CLASS 63:CLASS
64:CLASS 66:CLASS 67:Atom 68:Atom 69:Atom 70:CLASS 71:CLASS 72:Atom
73:CLASS 74:CLASS 75:CLASS 77:CLASS 78:CLASS 79:CLASS 80:CLASS 81:CLASS

82:CLASS

Generic attributes :

74:

Saturation : Saturated

Number of Carbon Atoms : 7 or more

Type of Ring System : Polycyclic

L39 3 SEA FILE=REGISTRY SUB=L8 SSS FUL (L32 OR L33 OR L34).

100.0% PROCESSED 2277 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

(FILE 'HOME' ENTERED AT 11:21:28 ON 12 SEP 2007)

FILE 'REGISTRY' ENTERED AT 11:21:35 ON 12 SEP 2007

FILE 'CAPLUS' ENTERED AT 11:21:38 ON 12 SEP 2007

E US2005-525784/APPS

L1 1 SEA ABB=ON US2005-525784/AP

D SCAN

SEL RN

FILE 'REGISTRY' ENTERED AT 11:22:26 ON 12 SEP 2007

L2 176 SEA ABB=ON (110865-90-2/BI OR 112848-47-2/BI OR 118395-73-6/BI
 OR 118693-63-3/BI OR 1404-55-3/BI OR 1404-90-6/BI OR 61036-62-
 2/BI OR 103-72-0/BI OR 104581-72-8/BI OR 104581-77-3/BI OR
 111465-73-7/BI OR 114894-40-5/BI OR 116528-12-2/BI OR 119789-44-
 5/BI OR 121844-63-1/BI OR 122172-99-0/BI OR 123631-08-3/BI OR
 133376-45-1/BI OR 135157-94-7/BI OR 137709-99-0/BI OR 137710-10-
 2/BI OR 164515-56-4/BI OR 164515-57-5/BI OR 171099-12-0/BI OR
 174421-39-7/BI OR 185461-61-4/BI OR 185461-67-0/BI OR 193685-70-
 0/BI OR 193685-71-1/BI OR 193685-72-2/BI OR 193742-05-1/BI OR
 204332-65-0/BI OR 204332-66-1/BI OR 204332-67-2/BI OR 204332-68-
 3/BI OR 204332-74-1/BI OR 204332-77-4/BI OR 204332-79-6/BI OR
 204332-82-1/BI OR 204332-84-3/BI OR 204332-85-4/BI OR 204332-88-
 7/BI OR 270927-20-3/BI OR 300582-65-4/BI OR 354123-19-6/BI OR
 410077-91-7/BI OR 410077-94-0/BI OR 508241-91-6/BI OR 508241-92-
 7/BI OR 508241-93-8/BI OR 562105-14-0/BI OR 562105-16-2/BI OR
 562105-17-3/BI OR 562105-18-4/BI OR 562105-19-5/BI OR 562105-20-
 8/BI OR 562105-21-9/BI OR 562105-22-0/BI OR 562105-23-1/BI OR
 562105-24-2/BI OR 562105-27-5/BI OR 562105-28-6/BI OR 562105-29-
 7/BI OR 562105-30-0/BI OR 562105-31-1/BI OR 562105-32-2/BI OR
 562105-33-3/BI OR 562105-34-4/BI OR 562105-35-5/BI OR 562105-36-
 6/BI OR 562105-38-8/BI OR 562105-40-2/BI OR 562105-41-3/BI OR
 562105-42-4/BI OR 562105-43-5/BI OR 562105-44-6/BI OR 562105-45-
 7/BI OR 562105-46-8/BI OR 562105-47-9/BI OR 562105-48-0/BI OR
 668993-07-5/BI OR 668993-09-7/BI OR 668993-11-1/BI OR 668993-13-
 3/BI OR 668993-14-4/BI OR 668993-15-5/BI OR 668993-16-6/BI OR
 668993-17-7/BI OR 668993-18-8/BI OR 668993-19-9/BI OR 668993-20-
 2/BI OR 668993-21-3/BI OR 668993-22-4/BI OR 668993-23-5/BI OR
 668993-25-7/BI OR 668993-26-8/BI OR 668993-27-9/BI OR 668993-28-
 0/BI OR 668993-29-1/BI OR 668993-30-4/BI OR 668993-31-5/BI OR
 668993-32-6/BI OR 668993-33-7/BI OR 668993-34-8/BI OR 668993-35-
 9/BI OR 668993-36-0/BI OR 668993-37-1/BI OR 668993-38-2/BI OR

668993-39-3/BI OR 668993-40-6/BI OR 668993-41-7/BI OR 668993-42
-8/BI OR 668993-43-9/BI
E RISTOMYCIN/CN

L3 1 SEA ABB=ON "RISTOMYCIN A"/CN
D SCAN
L4 STRUCTURE UPLOADED
L5 50 SEA SSS SAM L4
L6 0 SEA ABB=ON L5 AND L2
L7 7940 SEA SSS FUL L4 EXTEND
L8 7166 SEA SSS FUL L4
SAVE TEMP L8 MOH784FULL/A

FILE 'CAPLUS' ENTERED AT 11:49:45 ON 12 SEP 2007

L9 8578 SEA ABB=ON L8
L10 1 SEA ABB=ON L1 AND L9
D SCAN
E "AIDS (DISEASE)" +ALL/CT
E ANTI-AIDS AGENTS+ALL/CT
E ANTIVIRAL AGENTS+ALL/CT
E HUMAN IMMUNODEF/CT
E E7+ALL
L11 40388 SEA ABB=ON HUMAN IMMUNODEFICIENCY VIRUS+NT/CT
L12 49201 SEA ABB=ON ANTIVIRAL AGENTS+OLD/CT
L13 20238 SEA ABB=ON ANTI-AIDS AGENTS/CT
E "AIDS (DISEASE)" +OLD/CT
L14 21658 SEA ABB=ON "AIDS (DISEASE)" +OLD/CT
L15 167 SEA ABB=ON L9 AND (L11 OR L12 OR L13 OR L14)
L16 5597 SEA ABB=ON L9 AND (PY<2003 OR AY<2003 OR PRY<2003)
L17 93 SEA ABB=ON L16 AND (L11 OR L12 OR L13 OR L14)
L18 29 SEA ABB=ON L16 AND (L11 OR L13 OR L14)
L19 979 SEA ABB=ON BALZARINI J?/AU
L20 481 SEA ABB=ON PREOBRAZHENS KAYA M?/AU
L21 2099 SEA ABB=ON DECLERCQ E?/AU OR DE CLERCQ E?/AU
L22 35 SEA ABB=ON (L19 AND L20 AND L21) OR ((L19 OR L20 OR L21) AND
L9) OR (L1 AND L9)
L23 30 SEA ABB=ON ((L19 OR L20 OR L21) AND L9) OR (L1 AND L9)
L24 783 SEA ABB=ON (L19 AND (L20 OR L21)) OR (L20 AND L21)
L25 4 SEA ABB=ON (L24 AND L9) OR (L1 AND L9)
SAVE TEMP L25 MOH784CAAU/A
SAVE TEMP L18 MOH784AIDS/A

FILE 'REGISTRY' ENTERED AT 12:17:13 ON 12 SEP 2007

E ADAMANTYL
L26 4158 SEA ABB=ON ADAMANTYL
L27 0 SEA ABB=ON L2 AND L26
L28 170 SEA ABB=ON L2 AND CL/ELS
L29 173 SEA ABB=ON L8 AND L2

FILE 'ZCAPLUS' ENTERED AT 12:19:12 ON 12 SEP 2007

L30 7763 SEA ABB=ON L29

FILE 'REGISTRY' ENTERED AT 12:19:19 ON 12 SEP 2007

L31 21 SEA ABB=ON L29 AND TRICYCLO
L32 STRUCTURE UPLOADED
L33 STRUCTURE UPLOADED
L34 STRUCTURE UPLOADED
L35 0 SEA SUB=L8 SSS SAM (L32 OR L33 OR L34)

FILE 'LREGISTRY' ENTERED AT 13:00:03 ON 12 SEP 2007

E 2/CL

FILE 'REGISTRY' ENTERED AT 13:00:31 ON 12 SEP 2007
 L36 1445013 SEA ABB=ON 2/CL
 L37 5076 SEA ABB=ON L36 AND L8
 L38 2277 SEA SUB=L8 SSS FUL (L32 OR L33 OR L34) EXTEND
 L39 3 SEA SUB=L8 SSS FUL (L32 OR L33 OR L34)
 SAVE TEMP L39 MOH784SUB1/A

FILE 'ZCAPLUS' ENTERED AT 13:01:05 ON 12 SEP 2007
 L40 4 SEA ABB=ON L39
 D SCAN TI

FILE 'CAPLUS' ENTERED AT 13:01:27 ON 12 SEP 2007
 L41 4 SEA ABB=ON L39
 L42 4 SEA ABB=ON L25 AND L41

FILE 'CAPLUS' ENTERED AT 13:06:28 ON 12 SEP 2007
 D QUE NOS L25
 L43 4 SEA ABB=ON (L19 OR L20 OR L21) AND (L11 OR L12 OR L13 OR L14)
 AND L9
 L44 4 SEA ABB=ON (L25 OR L43)
 D QUE NOS L43
 L45 4 SEA ABB=ON (L25 OR L43)
 D IBIB ABS HITIND HITSTR L45 1-4
 SEL HIT RN L45 1-4

FILE 'REGISTRY' ENTERED AT 13:09:22 ON 12 SEP 2007
 D STAT QUE L8

FILE 'CAPLUS' ENTERED AT 13:09:22 ON 12 SEP 2007
 D QUE NOS L18
 L46 28 SEA ABB=ON L18 NOT L45
 D IBIB ABS HITIND HITSTR L46 1-28

FILE 'REGISTRY' ENTERED AT 13:10:29 ON 12 SEP 2007
 D STAT QUE L39

FILE 'CAPLUS' ENTERED AT 13:10:29 ON 12 SEP 2007
 L47 4 SEA ABB=ON L39
 D SCAN TI
 D STAT QUE L39
 D SAVED
 D QUE NOS L47

FILE 'STNGUIDE' ENTERED AT 13:24:13 ON 12 SEP 2007

FILE 'CAPLUS' ENTERED AT 13:40:46 ON 12 SEP 2007
 D QUE NOS L47
 L48 4 SEA ABB=ON (L19 OR L20 OR L21) AND L47
 D QUE NOS L48
 D IBIB ABS HITSTR L48 1-4

Mohamed, Abdel

From: O'Bryen, Barbara
Sent: Wednesday, September 12, 2007 1:57 PM
To: SCORE Support
Cc: Mohamed, Abdel
Subject: 10525784-ssr



20070912-1052578
4-str.zip

Ex Mohamed,

This search will become available on SCORE within the next few days. I'm sending you this advance copy because it is near the end of the fiscal year.

pp. 1-10 are the inventor search

pp. 11-106 are the search of the broad structures of claim 23 + AIDS/HIV

pp.106-113 are the species search

pp. 114-121 are the search history

Please let me know if you have any questions.

Barb
x22518